Small molecules useful in the treatment of inflammatory disease

专利摘要:
The present invention relates to methods for treating or preventing inflammatory and immune cell-mediated diseases by administering certain novel and known small molecule compounds. Examples of novel compounds are , , , , And
公开号:KR20000075893A
申请号:KR1019997007972
申请日:1998-03-03
公开日:2000-12-26
发明作者:켈리테렌스알프레드；보만바바라제인；프리에리아린；위지앙-핑
申请人:데이비드 이. 프랭크하우저；베링거 인겔하임 파마슈티칼즈, 인코포레이티드；
IPC主号:

专利说明:

Small molecules useful in the treatment of inflammatory disease
[2] Research over the last few years has clarified the molecular events involved in cell-cell interactions in vivo, particularly those related to the movement and activation of cells in the immune system. Conventional references: Springer, T. Nature, 1990, 346, 425-434. Cell surface proteins, and in particular cellular adhesion molecules (“CAMs”), including LFA-1, MAC-1 and gp150.95 (referred to in the WHO nomenclature as CD18 / CD11a, CD18 / CD11b and CD18 / CD11c, respectively) and “ Leukointegrins "have been the subject of pharmaceutical research and development aimed at correspondingly leukocyte extravasation to the site of injury and intervention during leukocyte migration to specific targets. For example, activation of constitutively expressed integrins in leukocytes occurs prior to leukocyte extravasation, an essential component of the current inflammatory response, followed by expression on integrins (eg LFA-1) and vascular endothelial cell surfaces and other leukocytes. Solid ligand / receptor interactions occur between one or several specific intercellular adhesion molecules (ICAMs), referred to as ICAM-1, ICAM-2, ICAM-3 or ICAM-4. The interaction of CAMs with leukointegrin is a critical step in the normal functionalization of the immune system. Immune methods such as antigen presentation, T-cell mediated cell destruction and leukocyte extravasation all require cellular adhesion mediated by ICAMs that interact with leukointegrin. Conventional references: Kishimoto, T. K .; Rothlein; R. R. Adv. Pharmacol. 1994, 25: 117-138 and Diamond, M .: Springer, T. Current Biology, 1994, 4, 506-532.
[3] Groups of individuals have been shown to lack adequate expression of leukointegrin, a condition referred to as "leukocyte adhesion deficiency". Anderson, D.C .; et al., Fed. Proc. 1985, 44, 2671-2677 and Anderson, D. C .; et al., J. Infect. Dis. 1985, 152, 668-689. Such individuals are unable to develop normal inflammatory and / or immune response (s) due to their inability to adhere to the cellular matrix. This information shows that the immune response is alleviated when lymphocytes cannot adhere in the normal way due to the lack of functional adhesion molecules of the CD18 group. It is believed that antagonism of the CD18, CD11 / ICAM-1 interaction can also inhibit the inflammatory response, due to the fact that LAD patients deficient in CD18 cannot elicit an inflammatory response.
[4] It has been demonstrated that antagonism of the interaction between CAMs and leucointegrin can be realized by reagents directly linked to another component. Specifically, blocking of CAMs such as ICAM-1, or leucointegrin such as, for example, LFA-1, by antibodies directed directly to one or both of these molecules effectively inhibits the inflammatory response. In vitro models of inflammatory and immune responses suppressed by antibodies to CAMs or leucointegrins include antigen or mitogen-induced lymphocyte proliferation, homogenous aggregation of lymphocytes, T-cell mediated cytolysis and antigen-specific induced Includes resistance. Feasibility of in vitro studies is supported by in vivo studies using antibodies directed directly to ICAM-1 or LFA-1. For example, antibodies directed directly to LFA-1 can prevent thyroid graft rejection and prolong cardiac metastasis viability in mice [Gorski, A .; Immunology Today, 1994, 15, 251-255. Most importantly, antibodies directed directly to ICAM-1 have been shown to be effective in vivo as anti-inflammatory agents in human diseases such as renal tagograft rejection and rheumatoid arthritis. Rothlein, R. R .; Scharschmidt, L., in: Adhesion Molecules; Wegner, C. D., Ed .; 1994, 1-38, Cosimi, C. B; et al., J. Immunol. 1990, 144, 4604-4612 and Kavanaugh, A .; et al., Arthritis Rheum. 1994, 37, 992-1004] and antibodies directed directly to LFA-1 have been shown to have immunosuppressive efficacy in preventing bone marrow transplantation and early rejection of kidney tagging [Fischer, A ,; et al., Lancet, 1989, 2, 1058-1060 and Le Mauff, B .; et al., Transplantation, 1991, 52, 291-295.
[5] It has also been demonstrated that the recombinant soluble form of ICAM-1 can act as an inhibitor of ICAM-1 interaction with LFA-1. Soluble ICAM-1 acts as a direct antagonist of CD18, CD11 / ICAM-1 interactions in cells, and is responsible for the proliferation of T cells from diabetic patients in response to human mixed lymphocyte responses, cytotoxic T cell responses, and islet cells. Show an inhibitory activity in an in vivo model of the immune response. Becker, JC; et al., J. Immunol. 1993, 151, 7224 and Roep, B. O .; et al., Lancet, 1994, 343, 1590.
[6] Thus, previous techniques have shown that large protein molecules that antagonize the binding of CAMs to lucointegrin have therapeutic potential in alleviating the inflammatory and immunological responses often associated with lesions of many autoimmune or inflammatory diseases. Proved. However, proteins have significant drawbacks as therapeutic agents, including the inability to transport oral and latent immunoreactives that limit the use of these molecules for chronic administration. In addition, protein-based therapeutics are generally expensive to manufacture.
[7] It is assumed that small molecule compounds with similar ability to macromolecular molecules capable of antagonizing the binding of CAMs to leucointegrin can be used to prepare desirable therapeutics. However, to date no small molecule compounds have been reported that act as direct antagonists.
[8] Several small molecule compounds that affect the interaction of CAMs with leukointegrin have been described in the literature. Natural products isolated from Trichyilia rubra have been found to be inhibitory in in vitro binding assays. Musza, L. L .; et al., Tetrahedron, 1994, 50, 11369-11378. A series of molecules [Boschelli, D. H .; et al., J. Med. Chem. 1994, 37, 717 and Boschelli, D. H .; et al., J. Med. Chem. 1995, 38, 4597-4614 have been shown to be orally active in the reversible passive Arthus response, an induction model of inflammation characterized by neutrophil accumulation (Chang, Y. H .; et al., Eur. J. Pharmacol. 1992, 69, 155-164]. Another series of molecules has also been found to be oral activity in the delayed type of hypersensitivity reactions in rats. Sanfilippo, P. J .; et al., J. Med. Chem. 1995, 38, 1057-1059. All of these molecules, along with another protein, appear to inhibit leukointegrin activation by unknown mechanisms by acting nonspecifically by inhibiting the transcription of ICAM-1 or by intracellular mechanisms. None of the molecules directly antagonize the interaction of CAMs with leukointegrin. Due to lack of potency, lack of sensitivity, and lack of specific mechanisms for activity, the small molecule compounds described above appear unsatisfactory for therapeutic use.
[9] Based on the state of the art, there is still a clear need for therapeutically useful small molecule compounds that have the ability to antagonize the interaction of CAMs with leukointegrin.
[10] Summary of the Invention
[11] A first aspect of the invention includes methods for treating or preventing inflammatory and immune cell-mediated disease (s) by administering certain novel and known small molecule compounds. Such compounds inhibit the interaction of cellular adhesion molecules, thereby specifically affecting leucointegrins of human intercellular adhesion molecules (including, for example, ICAM-1, ICAM-2, and ICAM-3) (eg, CD18 / CD11a). And CD18 / CD11b). A second aspect of the present invention includes novel small molecule compounds having the abovementioned therapeutic activity. A third aspect of the present invention includes a method for preparing such a novel compound. The final aspect of the invention includes pharmaceutical compositions comprising the above-mentioned compounds suitable for the prophylaxis or treatment of inflammatory and immune cell-mediated condition (s).
[1] The present invention generally relates to a series of novel small molecule compounds, their preparation and their use in the treatment of inflammatory diseases. The invention also relates to the use of similar but known compounds in the treatment of inflammatory diseases.
[12] In its first aspect, the present invention encompasses methods for treating or preventing inflammatory and immune cell-mediated diseases by administering novel and known specific small molecule compounds of Formula (I) or pharmaceutically acceptable salts thereof.
[13]
[14] In the above formula,
[15] Y is oxygen or sulfur atom,
[16] Z is oxygen or sulfur atom,
[17] X is a divalent group of the formula> CHR ¹ ,> NR ¹ ,> CHSO ₂ R ¹ or> NSO ₂ R ¹ , or an oxygen or sulfur atom, wherein R ¹ is
[18] (A) a hydrogen atom,
[19] (B) an alkyl or cycloalkyl group is
[20] (Iii) halogen,
[21] (Ii) oxo,
[22] (Iii) one or more hydrogen atoms of the aryl group are each optionally
[23] (a) alkyl of 1 to 3 carbon atoms,
[24] (b) -COOH,
[25] (c) -SO ₂ OH,
[26] (d) -PO (OH) ₂ ,
[27] (e) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[28] (f) R ⁸ and R ⁹ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or R ⁸ and R ⁹ are nitrogen atoms in between; A group of formula -NR ⁸ R ⁹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together form a heterocyclic ring;
[29] (g) R ¹⁰ and R ¹¹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁰ and R ¹¹ together with the nitrogen atom therebetween form a heterocyclic ring A group of formula -CONR ¹⁰ R ¹¹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
[30] (h) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
[31] (i) a group of formula -SR ^12b wherein R ^12b is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
[32] (j) cyano, or
[33] (k) R ¹³ , R ¹⁴ and R ¹⁵ are each independently a hydrogen atom or alkyl of 1 to 3 carbon atoms, and two of R ¹³ , R ¹⁴ and R ¹⁵ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Phenyl, naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, which may be substituted by an amidino group of Isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, triazinyl, indolinyl, isoindoleyl, benzo [b] furanyl, benzo [b] thiophenyl, indazolyl, Consisting of benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, furinyl, quinolininyl, cinnolinyl, phthalanyl, quinoxalinyl, naphthyridinyl, pterridinyl and quinazolinyl Aryl selected from the class,
[34] (Iii) a group of formula -COOR ¹⁶ wherein R ¹⁶ is straight or branched chain alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
[35] (Iii) cyano,
[36] (Iii) R ¹⁷ and R ¹⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁷ and R ¹⁸ together with the nitrogen atom therebetween form a heterocyclic ring; A group of formula -CONR ¹⁷ R ¹⁸ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
[37] (Iii) a group of formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
[38] (Iii) a group of formula -SR ²⁰ wherein R ²⁰ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
[39] (Iii) R ²¹ and R ²² are each independently
[40] (a) a hydrogen atom,
[41] (b) alkyl or acyl or cycloalkyl of 3 to 7 carbon atoms,
[42] (c) a group of the formula-(CH ₂ ) _m COOH, wherein m is 0, 1 or 2, or
[43] (d) a group of the formula-(CH ₂ ) _n COOR ²³ , wherein n is 0, 1 or 2 and R ²³ is straight or branched chain alkyl of 1 to 6 carbon atoms, or R ²¹ and R ²² are between A group of formula -NR ²¹ R ²² constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of
[44] (Iii) chemical formula Wherein R ²⁴ , R ²⁵ and R ²⁶ are each independently a branched or straight chain alkyl group having 1 to 7 carbon atoms and Q ⁻ is a chlorine, bromine or iodine counterion. Branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
[45] (C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
[46] (D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
[47] (E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
[48] (F) chemical formula (Where r is 2, 3, 4, 5 or 6, R ²⁷ , R ²⁸ and R ²⁹ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, and 2 of R ²⁷ , R ²⁸ and R ²⁹ ) May also constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom (s) therebetween form a heterocyclic ring,
[49] (G) chemical formula (Wherein s is 2, 3, 4, 5 or 6, R ³⁰ , R ³¹ , R ³² and R ³³ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, R ³⁰ , R ³¹ , R ³² And two of R ³³ may also constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom (s) therebetween form a heterocyclic ring;
[50] The nitrogen atom of the (H) group optionally
[51] (Iii) alkyl having 1 to 3 carbon atoms,
[52] (Ii) carboxylic ester groups having 2 to 7 carbon atoms,
[53] (Iii) a carboxylic acid group having 2 to 5 carbon atoms,
[54] (Iii) a phosphoric acid group having 1 to 6 carbon atoms, or
[55] (Iii) piperidyl substituted with sulfuric acid groups of 1 to 6 carbon atoms, or
[56] (I) one or more hydrogen atoms of the aryl group are each optionally
[57] (Iii) alkyl having 1 to 3 carbon atoms,
[58] (Ii) -COOH,
[59] (Iii) -SO ₂ OH,
[60] (Iii) -PO (OH) ₂ ,
[61] (Iii) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[62] (Iii) R ⁸ and R ⁹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁸ and R ⁹ are nitrogen atoms in between; A group of formula -NR ⁸ R ⁹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together form a heterocyclic ring;
[63] (Iii) R ¹⁰ and R ¹¹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁰ and R ¹¹ together with a nitrogen atom therebetween form a heterocyclic ring A group of formula -CONR ¹⁰ R ¹¹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
[64] (Iii) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
[65] (Iii) a group of formula -SR ^12b wherein R ^12b is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
[66] (x) cyano, or
[67] (xi) R ¹³ , R ¹⁴ and R ¹⁵ are each independently a hydrogen atom or alkyl of 1 to 3 carbon atoms, and two of R ¹³ , R ¹⁴ and R ¹⁵ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Phenyl, naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, which may be substituted by an amidino group of Isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, triazinyl, indolinyl, isoindoleyl, benzo [b] furanyl, benzo [b] thiophenyl, indazolyl, Consisting of benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, furinyl, quinolininyl, cinnolinyl, phthalanyl, quinoxalinyl, naphthyridinyl, pterridinyl and quinazolinyl Aryl selected from the class
[68] R ² is (A) a hydrogen atom, or
[69] (B) alkyl or cycloalkyl groups are optionally
[70] (Iii) a group of formula -OR ³⁴ wherein R ³⁴ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
[71] (Ii) side chains having 1 to 3 carbon atoms, each of which R ³⁵ and R ³⁶ may each independently be substituted with a group of formula —NR ³⁵ R ³⁶ wherein a hydrogen atom, alkyl having 1 to 2 carbon atoms or acyl having 1 to 2 carbon atoms; Straight chain alkyl or cycloalkyl having 3 to 5 carbon atoms,
[72] R ³ is a group of the formula-(CR ³⁷ R ³⁸ ) _x (CR ³⁹ R ⁴⁰ ) _y R ⁴¹ , wherein
[73] x and y are each independently 0 or 1,
[74] R ³⁷ , R ³⁸ and R ³⁹ are each independently
[75] (A) a hydrogen atom,
[76] (B) a group of formula -OR ⁴² , wherein R ⁴² is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
[77] (C) branched or straight chain alkyl of 1 to 3 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[78] R ⁴⁰ is (A) a hydrogen atom,
[79] (B) a group of formula -OR ⁴² , wherein R ⁴² is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
[80] (C) branched or straight chain alkyl of 1 to 3 carbon atoms or cycloalkyl of 3 to 5 carbon atoms, or
[81] (D) at least one hydrogen atom of the aryl group is each optionally
[82] (Iii) one or more hydrogen atoms of the aryl group are each optionally
[83] (a) branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
[84] (b) -COOH,
[85] (c) -SO ₂ OH,
[86] (d) -PO (OH) ₂ ,
[87] (e) a group of formula -COOR ⁴⁴ wherein R ⁴⁴ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[88] (f) R ⁴⁵ and R ⁴⁶ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁴⁵ and R ⁴⁶ being between A group of the formula -NR ⁴⁵ R ⁴⁶ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together with the nitrogen atom of form a heterocyclic ring;
[89] (g) R ⁴⁷ and R ⁴⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁴⁷ and R ⁴⁸ together with a nitrogen atom therebetween A group of formula -CONR ⁴⁷ R ⁴⁸ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a click ring,
[90] (h) a group of formula -OR ⁴⁹ wherein R ⁴⁹ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
[91] (i) a group of formula -SR ⁵⁰ wherein R ⁵⁰ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
[92] (j) cyano,
[93] (k) nitro,
[94] (l) R ⁵¹ , R ⁵² and R ⁵³ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, and two of R ⁵¹ , R ⁵² and R ⁵³ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Amidino group, or
[95] (m) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasingyl, 3-, 6- or 7-cinnolinyl, 6- or 7-phthalanilyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-phthalininyl and 2-, 6- or 7-quinazolinyl is selected from the class consisting of aryl R ^43,
[96] (Ii) methyl, which may be mono- or polysubstituted with a fluorine atom and mono-substituted with R ⁴³ ,
[97] (Iii) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
[98] (Iii) a group of formula -COOR ⁵⁴ wherein R ⁵⁴ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[99] (Iii) R ⁵⁵ and R ⁵⁶ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁵⁵ and R ⁵⁶ being between A group of the formula -NR ⁵⁵ R ⁵⁶ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of which one of R ⁵⁵ and R ⁵⁶ may also be a group R ⁴³ ,
[100] (Iii) R ⁵⁷ and R ⁵⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁵⁷ and R ⁵⁸ together with a nitrogen atom in between A group of formula -CONR ⁵⁷ R ⁵⁸ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which forms a click ring, wherein one of R ⁵⁷ and R ⁵⁸ may also be a group R ⁴³ ,
[101] (Iii) a group of formula -COR ⁵⁹ wherein R ⁵⁹ is a hydrogen atom, straight or branched chain alkyl of 1 to 5 carbon atoms, cycloalkyl of 3 to 5 carbon atoms or R ⁴³ ;
[102] (Iii) a group of formula -OR ⁶⁰ wherein R ⁶⁰ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁴³ ;
[103] (ix) a group of formula -SR ⁶¹ wherein R ⁶¹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁴³ ,
[104] (x) cyano,
[105] (xi) nitro, or
[106] (xii) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasing, 3-, 6- or 7-cinnolinyl , 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7- puteri Aryl selected from the group consisting of diyl and 2-, 6- or 7-quinazolinyl,
[107] R ⁴¹ is phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5 -Pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3- , 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- Or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6 Or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2-, 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3- , 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-quinolininyl, 3-, 6 Or 7-cinnolinyl, 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-phthyridinyl and 2-, 6- or 7-quinazolinyl Aryl selected from the group consisting of: wherein at least one hydrogen atom of said aryl group is
[108] (A) one or more hydrogen atoms of the aryl group are each optionally
[109] (Iii) branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
[110] (Ii) -COOH,
[111] (Iii) -SO ₂ OH,
[112] (Iii) -PO (OH) ₂ ,
[113] (Iii) a group of formula -COOR ⁶³ wherein R ⁶³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[114] (Iii) R ⁶⁴ and R ⁶⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁶⁴ and R ⁶⁵ being between A group of the formula -NR ⁶⁴ R ⁶⁵ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of
[115] (Iii) R ⁶⁶ and R ⁶⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁶⁶ and R ⁶⁷ together with a nitrogen atom therebetween A group of the formula -CONR ⁶⁶ R ⁶⁷ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring,
[116] (Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms;
[117] (ix) a group of formula -SR ⁶⁹ wherein R ⁶⁹ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
[118] (x) cyano,
[119] (xi) nitro, or
[120] (xii) R ⁷⁰ , R ⁷¹ and R ⁷² are each independently hydrogen atoms or alkyl or fluoroalkyl having 1 to 3 carbon atoms, and two of R ⁷⁰ , R ⁷¹ and R ⁷² are also nitrogen atom (s) in between; Formula with a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a heterocyclic ring together with Amidino group, or
[121] (xiii) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasing, 3-, 6- or 7-cinnoli , 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7- puteri R ⁶² , which is aryl selected from the group consisting of diyl and 2-, 6- or 7-quinazolinyl;
[122] (B) methyl, which may be mono- or polysubstituted with a fluorine atom and also monosubstituted with R ⁶² ,
[123] (C) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
[124] (D) a group of formula -COOR ⁷³ wherein R ⁷³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[125] (E) R ⁷⁴ and R ⁷⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or R ⁷⁴ and R ⁷⁵ between A group of formula -NR ⁷⁴ R ⁷⁵ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom of form a heterocyclic ring, one of R ⁷⁴ and R ⁷⁵ may also be a group R ⁶² ,
[126] (F) R ⁷⁶ and R ⁷⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁷⁶ and R ⁷⁷ together with a nitrogen atom therebetween A group of formula -CONR ⁷⁶ R ⁷⁷ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms forming a click ring, wherein one of R ⁷⁶ and R ⁷⁷ can also be a group R ⁶² ,
[127] (G) a group of formula -COR ⁷⁸ wherein R ⁷⁸ is a hydrogen atom, straight or branched chain alkyl of 1 to 5 carbon atoms, cycloalkyl of 3 to 5 carbon atoms or R ⁶² ,
[128] (H) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
[129] (I) a group of formula -SR ⁸⁰ wherein R ⁸⁰ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
[130] (J) cyano,
[131] (K) nitro, or
[132] (L) can be replaced with halogen,
[133] R ⁴ is Cl or trifluoromethyl,
[134] R ⁵ and R ⁶ are each independently hydrogen, fluorine, chlorine, bromine or iodine atoms, methyl or trifluoromethyl.
[135] As mentioned above, some of the compounds included in this class are known and described in US Pat. No. 3,668,217; US Patent No. 4,944,791; US Patent No. 3,741,981; Li, W.-Y; et al., J. Pharm. Sci. 1984, 73, 553-558 and Abd El Halim, M. S .; et al., Monatshefte fur Chemie, 1994, 125, 1437-1442.
[136] In a second aspect, the present invention includes novel compounds of formula (I) or pharmaceutically acceptable salts thereof.
[137] Formula I
[138]
[139] In the above formula,
[140] X, Y, Z, R ² , R ³ , R ⁴ , R ⁵ and R ⁶ are as defined above, provided that at least one hydrogen atom of the aryl group R ⁴¹ in residue R ³ is not necessarily any
[141] (A) one or more hydrogen atoms of the aryl group are each optionally
[142] (Iii) branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
[143] (Ii) -COOH,
[144] (Iii) -SO ₂ OH,
[145] (Iii) -PO (OH) ₂ ,
[146] (Iii) a group of formula -COOR ⁶³ wherein R ⁶³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[147] (Iii) R ⁶⁴ and R ⁶⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁶⁴ and R ⁶⁵ being between A group of the formula -NR ⁶⁴ R ⁶⁵ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of
[148] (Iii) R ⁶⁶ and R ⁶⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁶⁶ and R ⁶⁷ together with a nitrogen atom therebetween A group of the formula -CONR ⁶⁶ R ⁶⁷ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring,
[149] (Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms;
[150] (ix) a group of formula -SR ⁶⁹ wherein R ⁶⁹ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
[151] (x) cyano,
[152] (xi) nitro,
[153] (xii) R ⁷⁰ , R ⁷¹ and R ⁷² are each independently hydrogen atoms or alkyl or fluoroalkyl having 1 to 3 carbon atoms, and two of R ⁷⁰ , R ⁷¹ and R ⁷² are also nitrogen atom (s) in between; Formula with a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a heterocyclic ring together with Amidino group, or
[154] (xiii) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasing, 3-, 6- or 7-cinnoli , 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7- puteri R ⁶² , which is aryl selected from the group consisting of diyl or 2-, 6- and 7-quinazolinyl;
[155] (B) methyl, which may be mono- or polysubstituted with a fluorine atom and also monosubstituted with R ⁶² ,
[156] (C) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
[157] (D) a group of formula -COOR ⁷³ wherein R ⁷³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[158] (E) R ⁷⁴ and R ⁷⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or R ⁷⁴ and R ⁷⁵ between A group of formula -NR ⁷⁴ R ⁷⁵ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom of form a heterocyclic ring, one of R ⁷⁴ and R ⁷⁵ may also be a group R ⁶² ,
[159] (F) R ⁷⁶ and R ⁷⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁷⁶ and R ⁷⁷ together with a nitrogen atom therebetween A group of formula -CONR ⁷⁶ R ⁷⁷ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms forming a click ring, wherein one of R ⁷⁶ and R ⁷⁷ can also be a group R ⁶² ,
[160] (G) a group of formula -COR ⁷⁸ wherein R ⁷⁸ is a hydrogen atom, straight or branched chain alkyl of 1 to 5 carbon atoms, cycloalkyl of 3 to 5 carbon atoms or R ⁶² ,
[161] (H) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
[162] (I) a group of formula -SR ⁸⁰ wherein R ⁸⁰ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
[163] (J) cyano,
[164] (K) nitro, or
[165] (L) is replaced by halogen.
[166] Preferred novel compounds of formula (I) are
[167] Y is oxygen or sulfur atom,
[168] Z is oxygen or sulfur atom,
[169] X is a divalent group of formula> CHR ¹ ,> NR ¹ ,> CHSO ₂ R ¹ or> NSO ₂ R ¹ , or an oxygen or sulfur atom, wherein R ¹ is
[170] (A) a hydrogen atom,
[171] (B) an alkyl or cycloalkyl group is
[172] (Iii) halogen,
[173] (Ii) oxo,
[174] (Iii) one or more hydrogen atoms of the aryl group are each optionally
[175] (a) alkyl of 1 to 3 carbon atoms,
[176] (b) -COOH,
[177] (c) -SO ₂ OH,
[178] (d) -PO (OH) ₂ ,
[179] (e) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[180] (f) R ⁸ and R ⁹ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or R ⁸ and R ⁹ are nitrogen atoms in between; A group of formula -NR ⁸ R ⁹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together form a heterocyclic ring;
[181] (g) R ¹⁰ and R ¹¹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁰ and R ¹¹ together with the nitrogen atom therebetween form a heterocyclic ring A group of formula -CONR ¹⁰ R ¹¹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
[182] (h) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
[183] (i) a group of formula -SR ^12b wherein R ^12b is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
[184] (j) cyano, or
[185] (k) R ¹³ , R ¹⁴ and R ¹⁵ are each independently a hydrogen atom or alkyl of 1 to 3 carbon atoms, and two of R ¹³ , R ¹⁴ and R ¹⁵ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Phenyl, naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, which may be substituted by an amidino group of Isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, triazinyl, indolinyl, isoindoleyl, benzo [b] furanyl, benzo [b] thiophenyl, indazolyl, Consisting of benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, furinyl, quinolininyl, cinnolinyl, phthalanyl, quinoxalinyl, naphthyridinyl, pterridinyl and quinazolinyl Aryl selected from the class,
[186] (Iii) a group of formula -COOR ¹⁶ wherein R ¹⁶ is straight or branched chain alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
[187] (Iii) cyano,
[188] (Iii) R ¹⁷ and R ¹⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁷ and R ¹⁸ together with the nitrogen atom therebetween form a heterocyclic ring; A group of formula -CONR ¹⁷ R ¹⁸ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
[189] (Iii) a group of formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
[190] (Iii) a group of formula -SR ²⁰ wherein R ²⁰ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
[191] (Iii) R ²¹ and R ²² are each independently
[192] (a) a hydrogen atom,
[193] (b) alkyl or acyl or cycloalkyl of 3 to 7 carbon atoms,
[194] (c) a group of the formula-(CH ₂ ) _m COOH, wherein m is 0, 1 or 2, or
[195] (d) a group of the formula-(CH ₂ ) _n COOR ²³ , wherein n is 0, 1 or 2 and R ²³ is straight or branched chain alkyl of 1 to 6 carbon atoms, or R ²¹ and R ²² are between A group of formula -NR ²¹ R ²² constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of
[196] (Iii) chemical formula Where R ²⁴ , R ²⁵ and R ²⁶ are each independently a branched or straight chain alkyl group of 1 to 7 carbon atoms and Q ⁻ is a monosubstituted quaternary group of chlorine, bromine or iodine counterion, Branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
[197] (C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
[198] (D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
[199] (E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
[200] (F) chemical formula (Where r is 2, 3, 4, 5 or 6, R ²⁷ , R ²⁸ and R ²⁹ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, and 2 of R ²⁷ , R ²⁸ and R ²⁹ ) May also constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom (s) therebetween form a heterocyclic ring,
[201] (G) chemical formula (Wherein s is 2, 3, 4, 5 or 6, R ³⁰ , R ³¹ , R ³² and R ³³ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, R ³⁰ , R ³¹ , R ³² And two of R ³³ may also constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom (s) therebetween form a heterocyclic ring), or a guanidino group of
[202] The nitrogen atom of the (H) group optionally
[203] (Iii) alkyl having 1 to 3 carbon atoms,
[204] (Ii) carboxylic ester groups having 2 to 7 carbon atoms,
[205] (Iii) a carboxylic acid group having 2 to 5 carbon atoms,
[206] (Iii) a phosphoric acid group having 1 to 6 carbon atoms, or
[207] (Iii) piperidyl substituted with a sulfuric acid group having 1 to 6 carbon atoms,
[208] R ² is (A) a hydrogen atom, or
[209] (B) methyl,
[210] R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
[211] R ⁴¹ is phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5 -Pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3- , 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- Or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6 Or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2-, 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3- , 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-quinolininyl, 3-, 6 Or 7-cinnolinyl, 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-phthyridinyl and 2-, 6- or 7-quinazolinyl Aryl selected from the group consisting of: wherein at least one hydrogen atom of the aryl group is necessarily
[212] (A) one or more hydrogen atoms of the aryl group are each optionally
[213] (Iii) branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
[214] (Ii) -COOH,
[215] (Iii) -SO ₂ OH,
[216] (Iii) -PO (OH) ₂ ,
[217] (Iii) a group of formula -COOR ⁶³ wherein R ⁶³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[218] (Iii) R ⁶⁴ and R ⁶⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁶⁴ and R ⁶⁵ being between A group of the formula -NR ⁶⁴ R ⁶⁵ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of
[219] (Iii) R ⁶⁶ and R ⁶⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁶⁶ and R ⁶⁷ together with a nitrogen atom therebetween A group of the formula -CONR ⁶⁶ R ⁶⁷ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring,
[220] (Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms;
[221] (ix) a group of formula -SR ⁶⁹ wherein R ⁶⁹ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
[222] (x) cyano,
[223] (xi) nitro,
[224] (xii) R ⁷⁰ , R ⁷¹ and R ⁷² are each independently hydrogen atoms or alkyl or fluoroalkyl having 1 to 3 carbon atoms, and two of R ⁷⁰ , R ⁷¹ and R ⁷² are also nitrogen atom (s) in between; Formula with a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a heterocyclic ring together with Amidino group, or
[225] (xiii) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasing, 3-, 6- or 7-cinnoli , 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7- puteri R ⁶² , which is aryl selected from the group consisting of diyl and 2-, 6- or 7-quinazolinyl;
[226] (B) methyl, which may be mono- or polysubstituted with a fluorine atom and also monosubstituted with R ⁶² ,
[227] (C) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
[228] (D) a group of formula -COOR ⁷³ wherein R ⁷³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[229] (E) R ⁷⁴ and R ⁷⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or R ⁷⁴ and R ⁷⁵ between A group of formula -NR ⁷⁴ R ⁷⁵ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom of form a heterocyclic ring, one of R ⁷⁴ and R ⁷⁵ may also be a group R ⁶² ,
[230] (F) R ⁷⁶ and R ⁷⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁷⁶ and R ⁷⁷ together with a nitrogen atom therebetween A group of formula -CONR ⁷⁶ R ⁷⁷ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms forming a click ring, wherein one of R ⁷⁶ and R ⁷⁷ can also be a group R ⁶² ,
[231] (G) a group of formula -COR ⁷⁸ wherein R ⁷⁸ is a hydrogen atom, straight or branched chain alkyl of 1 to 5 carbon atoms, cycloalkyl of 3 to 5 carbon atoms or R ⁶² ,
[232] (H) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
[233] (I) a group of formula -SR ⁸⁰ wherein R ⁸⁰ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
[234] (J) cyano,
[235] (K) nitro, or
[236] (L) replaced by halogen,
[237] R ⁴ is Cl or trifluoromethyl,
[238] R ⁵ and R ⁶ are each independently hydrogen, fluorine, chlorine, bromine or iodine atoms, methyl or trifluoromethyl, or a pharmaceutically acceptable salt thereof.
[239] More preferably
[240] Y is an oxygen atom,
[241] Z is an oxygen atom,
[242] X is a divalent group of formula> CHR ¹ or> NR ¹ , wherein R ¹ is
[243] (A) a hydrogen atom,
[244] (B) an alkyl or cycloalkyl group is
[245] (Iii) oxo, or
[246] (Ii) one or more hydrogen atoms of the aryl group are each optionally
[247] (a) alkyl of 1 to 3 carbon atoms,
[248] (b) -COOH,
[249] (c) -SO ₂ OH,
[250] (d) -PO (OH) ₂ ,
[251] (e) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[252] (f) a group of the formula -NH ₂ ,
[253] (g) a group of the formula -CONH ₂ ,
[254] (h) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or methyl,
[255] (i) R ¹³ , R ¹⁴ and R ¹⁵ are each a hydrogen atom Amidino group,
[256] (j) a group of formula -COOR ¹⁶ wherein R ¹⁶ is straight or branched chain alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
[257] (k) a group of formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
[258] (l) chemical formula Phenyl, thiophenyl, pyridyl, pyrimidinyl, which may be substituted by quaternary groups, wherein R ²⁴ , R ²⁵ and R ²⁶ are each methyl and Q ⁻ is a chlorine, bromine or iodine counterion; From the class consisting of furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiazozolyl, pyridazinyl, pyrazinyl and triazinyl Branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which may be monosubstituted with selected aryl,
[259] (C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
[260] (D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
[261] (E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
[262] (F) chemical formula An amidino group, wherein r is 2, 3, 4, 5 or 6, and R ²⁷ , R ²⁸ and R ²⁹ are each hydrogen atoms,
[263] (G) chemical formula Guanidino groups, wherein s is 2, 3, 4, 5 or 6, and R ³⁰ , R ³¹ , R ³² and R ³³ are each hydrogen atoms, or
[264] The nitrogen atom of the (H) group optionally
[265] (Iii) alkyl having 1 to 3 carbon atoms,
[266] (Ii) carboxylic ester groups having 2 to 7 carbon atoms,
[267] (Iii) a carboxylic acid group having 2 to 5 carbon atoms,
[268] (Iii) a phosphoric acid group having 1 to 6 carbon atoms, or
[269] (Iii) piperidyl substituted with a sulfuric acid group having 1 to 6 carbon atoms,
[270] R ² is (A) a hydrogen atom, or
[271] (B) methyl,
[272] R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
[273] R ⁴¹ is phenyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, isothiazolyl, oxadizolyl, triazolyl, thiadia Aryl selected from the group consisting of zolyl, pyridazinyl, pyrazinyl and triazinyl, wherein at least one hydrogen atom of the aryl group is necessarily independently
[274] (A) one or more hydrogen atoms of the aryl group are each optionally
[275] (Iii) methyl,
[276] (Ii) -COOH,
[277] (Iii) -SO ₂ OH,
[278] (Iii) -PO (OH) ₂ ,
[279] (Iii) a group of formula -COOR ^{63 wherein} R ⁶³ is methyl,
[280] (Iii) R⁶⁴And R⁶⁵Are each independently a hydrogen atom or methyl⁶⁴R⁶⁵Of groups,
[281] (Iii) a group of formula -CONR ⁶⁶ R ⁶⁷ wherein R ⁶⁶ and R ⁶⁷ are each independently hydrogen or methyl;
[282] (Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or methyl;
[283] (ix) a group of formula -SR ⁶⁹ wherein R ⁶⁹ is a hydrogen atom or methyl,
[284] (x) cyano,
[285] (xi) nitro, or
[286] (xii) phenyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, isothiazolyl, oxadia, which may be replaced by halogen R ⁶² , which is an aryl selected from the group consisting of zolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl and triazinyl;
[287] (B) methyl, which may be mono- or polysubstituted with a fluorine atom and also monosubstituted with R ⁶² ,
[288] (C) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
[289] (D) a group of formula -COOR ^{73 wherein} R ⁷³ is methyl,
[290] (E) a group of formula -NR ⁷⁴ R ⁷⁵ , wherein R ⁷⁴ and R ⁷⁵ are each independently a hydrogen atom or methyl, and one of R ⁷⁴ and R ⁷⁵ can also be a group R ⁶² ,
[291] (F) a group of formula -CONR ⁷⁶ R ⁷⁷ , wherein R ⁷⁶ and R ⁷⁷ are each independently a hydrogen atom or methyl, and one of R ⁷⁶ and R ⁷⁷ can also be a group R ⁶² ,
[292] (G) a group of formula -COR ^{78 wherein} R ⁷⁸ is a hydrogen atom, methyl or R ⁶² ,
[293] (H) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, methyl or R ⁶² ,
[294] (I) a group of formula -SR ⁸⁰ , wherein R ⁸⁰ is a hydrogen atom, methyl or R ⁶² ,
[295] (J) cyano,
[296] (K) nitro, or
[297] (L) replaced by halogen,
[298] R ⁴ is Cl or trifluoromethyl,
[299] R ⁵ is a hydrogen atom,
[300] The novel compounds of formula (I) wherein R ⁶ is Cl or trifluoromethyl are or pharmaceutically acceptable salts thereof.
[301] Even more preferably
[302] Y is an oxygen atom,
[303] Z is an oxygen atom,
[304] X is a divalent group of formula> CHR ¹ or> NR ¹ , wherein R ¹ is
[305] (A) a hydrogen atom,
[306] (B) an alkyl or cycloalkyl group is
[307] (Iii) oxo, or
[308] (Ii) one or more hydrogen atoms of the aryl group are each optionally
[309] (a) alkyl of 1 to 3 carbon atoms,
[310] (b) -COOH,
[311] (c) -SO ₂ OH,
[312] (d) -PO (OH) ₂ ,
[313] (e) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
[314] (f) a group of the formula -NH ₂ ,
[315] (g) a group of the formula -CONH ₂ ,
[316] (h) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or methyl,
[317] (i) R ¹³ , R ¹⁴ and R ¹⁵ are each a hydrogen atom Amidino group,
[318] (j) a group of formula -COOR ¹⁶ wherein R ¹⁶ is straight or branched chain alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
[319] (k) a group of formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
[320] (l) chemical formula Phenyl, thiophenyl, pyridyl, pyrimidinyl, which may be substituted by quaternary groups, wherein R ²⁴ , R ²⁵ and R ²⁶ are each methyl and Q ⁻ is a chlorine, bromine or iodine counterion; From the class consisting of furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiazozolyl, pyridazinyl, pyrazinyl and triazinyl Branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, which may be monosubstituted with selected aryl,
[321] (C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
[322] (D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
[323] (E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
[324] (F) chemical formula An amidino group, wherein r is 2, 3, 4, 5 or 6, and R ²⁷ , R ²⁸ and R ²⁹ are each hydrogen atoms,
[325] (G) chemical formula Guanidino groups, wherein s is 2, 3, 4, 5 or 6, and R ³⁰ , R ³¹ , R ³² and R ³³ are each hydrogen atoms, or
[326] The nitrogen atom of the (H) group optionally
[327] (Iii) alkyl having 1 to 3 carbon atoms,
[328] (Ii) carboxylic ester groups having 2 to 7 carbon atoms,
[329] (Iii) a carboxylic acid group having 2 to 5 carbon atoms,
[330] (Iii) a phosphoric acid group having 1 to 6 carbon atoms, or
[331] (Iii) piperidyl substituted with a sulfuric acid group having 1 to 6 carbon atoms,
[332] R ² is (A) a hydrogen atom, or
[333] (B) methyl,
[334] R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
[335] R ⁴¹ is selected from the group consisting of phenyl, thiophenyl, pyridyl, pyrimidinyl, furyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl and pyrazinyl Aryl, wherein at least one hydrogen atom of the aryl group is necessarily
[336] (A) one or more hydrogen atoms of the aryl group are each optionally
[337] (Iii) methyl,
[338] (Ii) -COOH,
[339] (Iii) a group of formula -COOR ^{63 wherein} R ⁶³ is methyl,
[340] (Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or methyl; or
[341] (Iii) phenyl, thiophenyl, pyridyl, pyrimidinyl, furyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, which may be replaced by halogen, and R ⁶² , which is aryl selected from the group consisting of pyrazinyl,
[342] (B) methyl, which may be mono- or polysubstituted with a fluorine atom and also monosubstituted with R ⁶² ,
[343] (C) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
[344] (D) a group of formula -COOR ^{73 wherein} R ⁷³ is methyl,
[345] (E) a group of formula -CONR ⁷⁶ R ⁷⁷ wherein R ⁷⁶ and R ⁷⁷ are each methyl, one of R ⁷⁶ and R ⁷⁷ is methyl and the other is group R ⁶² ,
[346] (F) a group of formula -COR ^{78 wherein} R ⁷⁸ is a hydrogen atom, methyl or R ⁶² ,
[347] (G) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, methyl or R ⁶² ,
[348] (H) cyano,
[349] (I) nitro, or
[350] (J) replaced with halogen,
[351] R ⁴ is Cl or trifluoromethyl,
[352] R ⁵ is a hydrogen atom,
[353] The novel compounds of formula (I) wherein R ⁶ is Cl or trifluoromethyl are or pharmaceutically acceptable salts thereof.
[354] Even more preferably
[355] Y is an oxygen atom,
[356] Z is an oxygen atom,
[357] X is a divalent group of formula> CHR ¹ or> NR ¹ , wherein R ¹ is
[358] (A) a hydrogen atom,
[359] (B) an alkyl or cycloalkyl group is
[360] (Iii) oxo, and
[361] (Ii) one or more hydrogen atoms of the aryl group are each optionally
[362] (a) alkyl of 1 to 3 carbon atoms,
[363] (b) -COOH,
[364] (c) -SO ₂ OH,
[365] (d) -PO (OH) ₂ ,
[366] (e) a group of formula -OR ^12a , wherein R ^12a is a hydrogen atom or methyl, or
[367] (f) Formulas R ¹³ , R ¹⁴ and R ¹⁵ are each hydrogen atoms Aryl selected from the group consisting of phenyl or pyridyl, which may be replaced by an amidino group of
[368] (Iii) a group of formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
[369] (Iii) chemical formula Branched or straight-chain alkyl or carbon atoms having 1 to 6 carbon atoms, which may be monosubstituted into quaternary groups, wherein R ²⁴ , R ²⁵ and R ²⁶ are each methyl and Q ⁻ is a chlorine, bromine or iodine counterion; 3 to 6 cycloalkyl,
[370] (C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
[371] (D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
[372] (E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
[373] (F) chemical formula An amidino group, wherein r is 2, 3, 4, 5 or 6, and R ²⁷ , R ²⁸ and R ²⁹ are each hydrogen atoms,
[374] (G) chemical formula Guanidino groups, wherein s is 2, 3, 4, 5 or 6, and R ³⁰ , R ³¹ , R ³² and R ³³ are each hydrogen atoms, or
[375] The nitrogen atom of the (H) group optionally
[376] (Iii) alkyl having 1 to 3 carbon atoms,
[377] (Ii) carboxylic ester groups having 2 to 7 carbon atoms,
[378] (Iii) a carboxylic acid group having 2 to 5 carbon atoms,
[379] (Iii) a phosphoric acid group having 1 to 6 carbon atoms, or
[380] (Iii) piperidyl substituted with a sulfuric acid group having 1 to 6 carbon atoms,
[381] R ² is (A) a hydrogen atom, or
[382] (B) methyl,
[383] R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
[384] R ⁴¹ is aryl selected from the group consisting of phenyl or pyridyl, wherein at least one hydrogen atom of the aryl group is necessarily
[385] (A) one or more hydrogen atoms of the aryl group are each optionally
[386] (Iii) methyl,
[387] (Ii) -COOH,
[388] (Iii) a group of formula -COOR ^{63 wherein} R ⁶³ is methyl,
[389] (Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or methyl; or
[390] (Iii) R ⁶² , which is aryl selected from the class consisting of phenyl or pyridyl, which may be replaced by halogen;
[391] (B) a fluorine atom-yl-methyl, or is optionally substituted or may be substituted by R ^62,
[392] (C) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted with fluorine or oxo,
[393] (D) a group of formula -COOR ^{73 wherein} R ⁷³ is methyl,
[394] (E) a group of formula -CONR ⁷⁶ R ⁷⁷ wherein R ⁷⁶ and R ⁷⁷ are each methyl, one of R ⁷⁶ and R ⁷⁷ is methyl and the other is group R ⁶² ,
[395] (F) a group of formula -COR ^{78 wherein} R ⁷⁸ is a hydrogen atom, methyl or R ⁶² ,
[396] (G) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, methyl or R ⁶² ,
[397] (H) cyano,
[398] (I) nitro, or
[399] (J) replaced with halogen,
[400] R ⁴ is a chlorine atom or trifluoromethyl,
[401] R ⁵ is a hydrogen atom,
[402] Is a novel compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R ⁶ is a chlorine atom or trifluoromethyl.
[403] Particularly preferred novel compounds of formula I are
[404] Y is an oxygen atom,
[405] Z is an oxygen atom,
[406] X is a divalent group of formula> CHR ¹ or> NR ¹ , wherein R ¹ is
[407] (A) a hydrogen atom,
[408] (B) (vi) oxo,
[409] (Ii) at least one hydrogen atom of the aryl group is optionally
[410] (a) alkyl of 1 to 3 carbon atoms,
[411] (b) -COOH,
[412] (c) -SO ₂ OH,
[413] (d) -PO (OH) ₂ ,
[414] (e) a group of formula -OR ^12a , wherein R ^12a is a hydrogen atom or methyl, or
[415] (f) Formulas R ¹³ , R ¹⁴ and R ¹⁵ are each hydrogen atoms Aryl selected from the class consisting of phenyl or pyridyl, which may be replaced by an amidino group of
[416] (Iii) alkyl having 1 to 2 carbon atoms which may be monosubstituted with a group of the formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or methyl,
[417] (C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
[418] (D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
[419] (E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
[420] (F) chemical formula An amidino group, wherein r is 2, 3, 4, 5 or 6, and R ²⁷ , R ²⁸ and R ²⁹ are each hydrogen atoms, or
[421] (G) chemical formula (Where s is 2, 3, 4, 5 or 6, and R ³⁰ , R ³¹ , R ³² and R ³³ are each hydrogen atoms), and are guanidino groups of
[422] R ² is (A) a hydrogen atom, or
[423] (B) methyl,
[424] R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
[425] R ⁴¹ is phenyl, wherein at least one hydrogen atom of the phenyl group is necessarily
[426] (A) one or more hydrogen atoms of the aryl group are each optionally
[427] (Iii) methyl,
[428] (Ii) a group of formula -COOR ^{63 wherein} R ⁶³ is methyl,
[429] (Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or methyl; or
[430] (Iii) R ⁶² , which is aryl selected from the class consisting of phenyl or pyridyl, which may be replaced by halogen;
[431] (B) a fluorine atom-yl-methyl, or is optionally substituted or may be substituted by R ^62,
[432] (C) a group of formula -COOR ^{73 wherein} R ⁷³ is methyl,
[433] (D) a group of formula -COR ^{78 wherein} R ⁷⁸ is methyl or R ⁶² ,
[434] (E) a group of the formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, methyl or R ⁶² ,
[435] (F) cyano,
[436] (G) nitro, or
[437] (H) replaced by halogen,
[438] R ⁴ is a chlorine atom or trifluoromethyl,
[439] R ⁵ is a hydrogen atom,
[440] R ⁶ is a chlorine atom or trifluoromethyl or a pharmaceutically acceptable salt thereof.
[441] More particularly preferred novel compounds of formula I are
[442] Y is an oxygen atom,
[443] Z is an oxygen atom,
[444] X is a divalent group of formula> NR ¹ , wherein R ¹ is
[445] (A) a hydrogen atom,
[446] (B) methyl or ethyl, or
[447] (C) -COCH ₃ ,
[448] R ² is (A) a hydrogen atom, or
[449] (B) methyl,
[450] R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
[451] R ⁴¹ is phenyl, wherein at least one hydrogen atom of the phenyl group is necessarily
[452] (A) one or more hydrogen atoms of the aryl group are each optionally
[453] (Iii) methyl,
[454] (Ii) a group of formula -COOR ^{63 wherein} R ⁶³ is methyl,
[455] (Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or methyl; or
[456] (Iii) R ⁶² , which is aryl selected from the class consisting of phenyl or pyridyl, which may be replaced by halogen;
[457] (B) a fluorine atom-yl-methyl, or is optionally substituted or may be substituted by R ^62,
[458] (C) a group of formula -COOR ^{73 wherein} R ⁷³ is methyl,
[459] (D) a group of formula -COR ^{78 wherein} R ⁷⁸ is methyl or R ⁶² ,
[460] (E) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is methyl or R ⁶² ,
[461] (F) cyano,
[462] (G) nitro, or
[463] (H) replaced by halogen,
[464] R ⁴ is a chlorine atom or trifluoromethyl,
[465] R ⁵ is a hydrogen atom,
[466] R ⁶ is a chlorine atom or trifluoromethyl or a pharmaceutically acceptable salt thereof.
[467] In addition, preferred novel compounds of formula (I)
[468] Y is an oxygen atom,
[469] Z is an oxygen atom,
[470] X is a divalent group of formula> NR ¹ , wherein R ¹ is
[471] (A) a hydrogen atom,
[472] (B) methyl or ethyl, or
[473] (C) -COCH ₃ ,
[474] R ² is (A) a hydrogen atom, or
[475] (B) methyl,
[476] R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
[477] R ⁴¹ is phenyl, wherein at least one hydrogen atom of the phenyl group is necessarily
[478] (A) one or more hydrogen atoms of the aryl group are each optionally
[479] (Iii) methyl, or
[480] (Ii) R ^{62 which is} aryl selected from the class consisting of phenyl or pyridyl, which may be replaced by halogen;
[481] (B) methyl, which may be mono- or polysubstituted with fluorine atoms,
[482] (C) a group of formula -COR ^{78 wherein} R ⁷⁸ is methyl or R ⁶² , or
[483] (D) replaced with halogen,
[484] R ⁴ is a chlorine atom,
[485] R ⁵ is a hydrogen atom,
[486] R ⁶ is a chlorine atom or a pharmaceutically acceptable salt thereof.
[487] Ultimately preferred compounds of formula I have a structure
[488]
[489] Certain compounds having or a pharmaceutically acceptable salt thereof.
[490] Synthesis of Compounds of the Invention
[491] Synthesis of compounds analogous to the compounds of the present invention is known in detail in the art. For the purposes of the inventors, some routes may be more suitable for providing small amounts of various compounds, while other routes may be more suitable for mass synthesis of certain compounds. Some routes to these compounds and examples of compounds synthesized by each route are illustrated next.
[492] Starting amino acids and derivatives thereof required for the synthesis of hydantoin and thio-hydantoin structures are commercially available or known literature processes [Williams, R.W. Synthesis of Optically Active α-Amino Acids; Peramon: Oxford, 1989, α-Amino Acid Synthesis; O'Donnell, M. J., Ed .: Tetrahedron Symposium in Print; Pergamon: London, 1988: Vol. 44, Issue 17, Jung, M.J. Chemistry and Biochemistry of the Amino Acids; Barrett, G. C., Ed .: Chapman and Hall: New York, 1985; p.227, and Spero, D. M .; Kapadia, S.R.J. Org. Chem. 1996, 61: 7398-7401. The synthesis and degradation of ethyl 2-amino-2- (4-bromobenzyl) -propanoate (starting material for Example 39) is shown by the examples.
[493] A solution of alanine ethyl ester hydrochloride (15.3 g, 99.3 mmol) in 60 mL of water is treated with triethylamine (14.6 mL, 104.8 mmol) at room temperature for 30 minutes. The mixture is then extracted twice with 100 ml of methylene chloride. The organic layers are combined, dried over sodium sulfate and concentrated in vacuo to yield 10.0 g (86% yield) of the free base of the amino ester. The residue is redissolved in methylene chloride and cooled in an ice bath. Magnesium sulfate (11.3 g, 93.9 mmol) is added followed by trimethyl acetaldehyde (9.3 mL, 85.6 mmol). The ice bath is removed and the mixture is stirred overnight. Magnesium sulfate is removed by filtration and the precipitate is concentrated in vacuo to give 11.8 g (74.6% yield) of imine intermediate.
[494] The imine (11.8 g, 63.7 mmol) prepared above was dissolved in toluene (90 mL). 4-bromobenzyl bromide (17.5 g, 70.1 mmol) is added and the reaction is cooled to about -10 ° C. Potassium tert-butoxide (8.6 g, 76.5 mmol) is added so that the temperature does not exceed 0 ° C. The reaction is stirred for 2 h in a cold bath, then diluted with ether and washed with water (150 mL). The organic layer is dried (sodium sulfate), filtered and concentrated in vacuo to afford a clear yellow oil. It is treated with 1N HCl (100 mL, 100 mmol) and stirred overnight. The reaction is extracted with ethyl acetate and 14.1 g (68.7% yield) of racemic amino ester hydrochloride in the aqueous layer.
[495] Racemic compounds can be decomposed into these component enantiomers through various known techniques. Ethyl 2- (R) -amino-2- (4-bromobenzyl) -propanoate (starting material for Example 29) was converted to racemic ethyl 2-amino-2- (4-bromobenzyl) -prop Prepared from panoate by the following procedure: 20 g of enzyme lipase L10 (Amano Enzyme USA Co., Ltd, Lombardi, IL) commercially available in 1.3 L buffer prepared with 13.69 g KH ₂ PO ₄ and 2 L water followed by racemic 12 g of HCl salt of amino ester are added. Observe the pH and add 1N KOH if necessary to fix the pH of the mixture to 6.4. The reaction process was observed by reversible phase HPLC and after 2 days HPLC analysis showed that 50.4% of the starting material was hydrolyzed. At this time, sufficient solid NaHCO ₃ is added to adjust the pH to 8.1 and the mixture is extracted twice with toluene, ether and EtOAc. The combined organic layers were dried and concentrated and the crude product was purified by silica gel chromatography (EtOAC: hexane) to give 5.21 g (87%) of ethyl 2- (R) -amino-2- (4-bromobenzyl) -propanoate ).
[496] Method A. Initiation using amino acids and phenylisocyanates. Currency using acid
[497] Suitable amino acids are dissolved in an aqueous base (eg, NaOH, KOH, Na ₂ CO ₃ , NaHCO ₃ , K ₂ CO ₃ or KHCO ₃ ) and warmed to about 20-90 ° C. Suitable isocyanates are added to the mixture and the resulting solution is stirred until the reaction is essentially complete. Upon cooling, the mixture is acidified and the resulting ureidoacetic acid is separated into an organic solvent by filtration or extraction. The solvent is removed to give intermediate ureidoacetic acid. In a manner as reported by Sauli (see US Pat. No. 4,099,008), intermediate ureidoacetic acid can be prepared in a catalytic amount in an organic or aqueous solvent (e.g. sulfuric acid, methanesulfonic acid, benzenesulfonic acid or hydrochloric acid). And cyclization by heating in the presence of) to produce the desired hydantoin. Hydantoin is recovered by purification and worked up by, for example, purification by silica gel chromatography or recrystallization.
[498] The compounds shown in Table 1 are prepared via this conventional method.
[499] Examples of Compounds Synthesized by Method A
[500]
[501]
[502]
[503]
[504] Method A is illustrated by the synthesis of the compound of Example 12 (see Table 1) and performed as follows. Homophenylalanine (1.00 g, 5.58 mmol) is dissolved in a solution of NaOH (0.28 g, 6.69 mmol) in H ₂ O (10.0 mL) and heated to 45 ° C. When the solution is homogeneous 3,5-dichlorophenyl isocyanate (1.05 g, 5.58 mmol) is added and the mixture is heated at 45 ° C. for an additional 2 hours. The cooled reaction mixture is then acidified with concentrated HCl to pH = 2-3. The precipitate is recovered by filtration, washed with water and dried in vacuo at 50 ° C. to afford intermediate ureidoacetic acid (crude yield, 42%). The intermediate is then taken up in a solution of concentrated HCl (50 mL) and water (5.0 mL) and heated at reflux for 5 h. The reaction mixture is then cooled to room temperature and the white solid is collected by suction filtration, washed with water and dried under vacuum at 50 ° C. to yield 0.52 g of crude hydantoin. This material was purified by recrystallization from EtOH to give 0.37 g (45%) of compound from Example 12.
[505] Method B. Initiation Using Amino Acids and Phenylisocyanates. Currency using EDC
[506] Suitable amino acids are dissolved in an aqueous base (eg, NaOH, KOH, Na ₂ CO ₃ , NaHCO ₃ , K ₂ CO ₃ or KHCO ₃ ) and warmed to about 20-90 ° C. Suitable isocyanates are added to the mixture and the resulting solution is stirred until the reaction is essentially complete. Upon cooling, the mixture is acidified and the resulting ureidoacetic acid is separated into an organic solvent by filtration or extraction. The solvent is removed to give intermediate ureidoacetic acid. The intermediate ureidoacetic acid is then reacted with an ester activator (eg 1-hydroxybenzotriazole hydrate (HOBT)) and a nonnucleophilic base (eg triethylamine or N, N-diisopropylethylamine). In the presence of various dehydrating agents (e.g., dicyclohexylcarbodiimide (DCC) or 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide HCl (EDC)) Cyclization to the desired hydantoin in DMF, NMP or THF). After extraction with an organic solvent it is worked up, for example, by purification via silica gel chromatography or recrystallization.
[507] The compounds shown in Table 2 are prepared via this conventional method.
[508] Examples of Compounds Synthesized by Method B
[509]
[510]
[511]
[512]
[513]
[514] Method B is illustrated by the synthesis of the compound of Example 15 (Table 2), carried out as follows: 3,5-dichlorophenyl isocyanate (1) in a solution of (R) -phenylalanine in 1 ml 2N NaOH and 10 ml water 0.38 g, 2 mmol). The resulting mixture is then stirred for 1 hour. The solution is cooled and treated with concentrated HCl until the precipitate formed and the solution is acidic. The precipitate is recovered by filtration and dried under vacuum to afford the desired acid (0.60 g, 85%). Ureidoacetic acid (0.35 g, 1 mmol) was dissolved in 20 mL of DMT and treated with EDC (0.19 g, 1 mmol) and HOBT (0.14 g, 1 mmol) at room temperature for 1 hour. After this time, N, N-diisopropylethylamine (0.35 mL, 2 mmol) is added and the mixture is stirred overnight. Hydantoin is recovered by filtration with water and worked up by purification by silica gel chromatography. The yield in this example is 0.20 g (60%).
[515] Method C. Initiation using amino esters or hydroxy esters and phenylisocyanates. Cyclization with bases or acids
[516] Suitable amino esters or hydroxy esters and suitable isocyanates are combined with organic solvents (eg DMF, THF) in the presence of a base (eg NaOH, KOH, Na ₂ CO ₃ , NaHCO ₃ , K ₂ CO ₃ or KHCO ₃ ). Or DMSO) and warm to about room temperature to 60 ° C. After about 1 hour, the reaction mixture is increased to about 50-100 ° C. until the reaction is complete. The solution is then cooled and diluted with an organic solvent (eg EtOAc or CH ₂ Cl ₂ ). The organic phase is washed successively with dilute aqueous acid (eg 1N HCl) and water, dried (eg in MgSO ₄ ) and concentrated. The desired hydantoin is purified, for example by silica gel chromatography or recrystallization. (The ureidoacetic acid ester can also be cyclized to hydantoin by heating to about 50-100 ° C. until the reaction is complete, for example in the presence of an acid such as aqueous HCl).
[517] The compounds shown in Table 3 are prepared via this conventional method.
[518] Examples of Compounds Synthesized by Method C
[519]
[520]
[521]
[522]
[523]
[524]
[525] Method C is illustrated by the synthesis of the compounds of Example 30 in Table 3, as follows: Methyl 2-amino-2-benzylbutyric acid (0.21 g, 1 mmol) and 3,5-dichlorophenyl isocyanate (0.19 g, 1 mmol) ) Is dissolved in DMSO (5 mL) in the presence of about 0.2 g of Na ₂ CO ₃ and allowed to stir at 50 ° C. for 1 hour. The solution is then heated to 90 ° C. for 2 hours. The solution is then cooled, diluted with EtOAc and washed with 0.1N HCl and water. The organic layer was dried over MgSO ₄ and concentrated to give the crude product which was further purified by silica gel chromatography to yield 0.12 g (33%) of the compound of Example 30.
[526] Method D. Solid Phase Synthesis
[527] Several examples have been described in the literature demonstrating that the synthesis of hydantoin and its precursor amino acid derivatives can be carried out in the solid phase, making the synthesis of these various compounds suitable for automated approaches. Examples of the synthesis of precursor amino acid derivatives are shown in J. American Chemical Society, 1996, 118, 6070-1, Tetrahedron Letters, 1997, 38, 7163-7166, Tetrahedron Letters, 1997, 38, 8821. . Cited documents demonstrating the conversion of such amino acid derivatives to hydantoin are described in J. Organic Chemistry 1997, 62, 6060-2.
[528] Amino acids attached to the solid resin via a carboxylic acid via a suitable binder (eg Wang resin: 4-benzyloxy-benzyl polystyrene) form an imine with alpha-carbon (e.g. Protected on that nitrogen using reagents that can allow alkylation of benzaldehyde derivatives). The protected compound is then treated with a base and an alkylating agent to produce a new protected amino acid derivative. The protecting group is removed using standard conditions (for imine, this is done using, for example, aqueous HCl) and the organic amino group is reacted with isocyanates to produce intermediate urea. This intermediate is treated with a reagent that forms the desired hydantoin and catalyzes the cyclization of the urea moiety to the carboxylate terminus of the molecule that degrades the product from the resin. Purification via silica gel chromatography, reversible phase HPLC of recrystallization.
[529] The compounds shown in Table 4 are prepared via this conventional method.
[530] Examples of Compounds Synthesized by Method D
[531]
[532]
[533]
[534]
[535]
[536]
[537]
[538]
[539]
[540]
[541] Method D is exemplified by the synthesis of the compound of Example 67, and is carried out as follows: The reaction vessel is commercially available Fmoc-Ala-Wang (300 mg, 0.150 mmol) and blood in N-methyl pyrrolidinone (NMP). Fill with 3 ml of 20% solution of ferridine. The reaction vessel is stirred for 45 minutes with an orbital shaker at room temperature. The resin is filtered off and washed with NMP (3 × 1 mL). The reaction vessel containing the resin is equipped with a rubber septum, placed under argon and filled with 3,4-dichlorobenzaldehyde (394 mg, 2.25 mmol), trimethyl orthoformate (3.5 mL) and NMP (1.5 mL). The resulting mixture is stirred at room temperature for 15 hours. The solid resin is separated by filtration and washed successively with NMP (3 × 3 mL), tetrahydrofuran (3 × 1 mL) and CH ₂ Cl ₂ (3 × 3 mL). The resin is then dried in vacuo for about 1 hour to obtain an imine-resin intermediate.
[542] Imine-resin intermediates were prepared as 2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine (BEMP, 0.217 mL, 0.75 mmol) and NMP (3.5). Ml) two reagents are mixed and the mixture is alkylated with 2,3-difluoro-4-trifluoromethylbenzyl bromide (123.8 mg, 0.45 mmol) by stirring at room temperature for 15 hours with an orbital shaker. The solid is separated by filtration and washed successively with NMP (3 × 3 mL), THF (3 × 3 mL) and CH ₂ Cl ₂ (3 × 3 mL) to give the alkylated-imine-resin intermediate upon drying. .
[543] Imine is digested from the intermediate by treatment with aqueous 1N HCl (1.8 mL) and THF (3.6 mL) and stirring at room temperature for about 15 hours. The resin bound amino esters are separated by filtration and washed successively with NMP (3 × 3 mL), THF (3 × 3 mL) and CH ₂ Cl ₂ (3 × 3 mL) and dried under vacuum.
[544] The resin bound amino esters are converted to hydantoin using a process that breaks down the final product from the resin. The intermediate amino-ester is placed in a reaction vessel and treated with 3 ml of a 20% solution of N, N-diisopropylethylamine in NMP. After stirring for 1 hour at room temperature under argon, the resin is filtered, washed with NMP (3 × 3 mL) and methanol (3 × 3 mL) and placed under vacuum. The vessel is then opened under argon and filled with 2.5 ml of a 1.75 M solution of 3,5-dichlorophenylisocyanate in dimethyformamide (DMF, 0.45 mmol). The mixture is stirred at room temperature under argon overnight and the product is removed from the resin by filtration. The resin was washed with ethyl acetate (6 × 2 mL), then the combined organic solutions were diluted with water and then washed with water (3 × 3 mL) and saturated aqueous NaCl (2 × 3 mL), dried over sodium sulfate and filtered, Concentrate under nitrogen stream. Final purification using reversible phase HPLC (acetonitrile-water gradient).
[545] Method E. Initiation with isocyanate-ester and arylene. Cyclization with bases or acids
[546] Suitable aniline is added to a suitable isocyanate ester dissolved in an organic solvent (eg methylene chloride) and the mixture is stirred at room temperature under an inert atmosphere such as argon for about 1 to 24 hours. The organic solvent is then removed under vacuum. Excess aniline is removed (such as by boiling the crude solid in hexane to decanter the liquid or by flash chromatography on silica gel) to give a solid ureidoacetic acid ester. The ureidoacetic acid ester is treated with a base (eg, NaH, NaHMDS, Na ₂ CO ₃ , NaHCO ₃ , K ₂ CO ₃ or KHCO ₃ ) in an organic solvent (eg THF or DMF) to give the desired hydantoin. And then warmed to about 60-90 ° C. The solution is then cooled and diluted with an organic solvent (eg EtOAc). The organic solution is diluted with dilute aqueous acid (eg 1N HCl) followed by water, dried (using MgSO ₄ ) and concentrated. The desired hydantoin is purified by silica gel chromatography or recrystallization. (Also, intermediate ureidoacetic acid esters can be cyclized to hydantoin by heating to about 90 ° C. in the presence of an acid such as aqueous HCl, as mentioned in Method C).
[547] The compounds shown in Table 5 are prepared via this method.
[548] Examples of Compounds Synthesized by Method E
[549] Method E is illustrated by the synthesis of the compounds from Example 70 shown in Table 5 and is carried out as follows: ethyl 2-isocyanate-3-phenylpropionate (99.0 mL) in anhydrous CH ₂ Cl ₂ (5.0 mL). , 0.110 g, 0.501 mmol) was added 3,4,5-trichloroaniline (0.1952 g, 0.994 mmol) as a solid. The mixture is stirred at room temperature under argon atmosphere for 20 hours. The solution is then concentrated in vacuo and the residue is recrystallized twice from ethyl acetate / hexanes to give 0.14 g (65%) of pure intermediate urea as a white solid. A suspension of sodium hydride (0.06 g 60% dispersion in mineral oil, 1.52 mmol) in anhydrous THF (4.0 mL) is treated with a solution of the urea (0.108 g, 0.260 mmol) in anhydrous THF (4.0 mL). The mixture is stirred at room temperature under argon atmosphere for 1 hour. The mixture is then poured into 100 ml of 1N aqueous HCl. THF is removed under reduced pressure and the mixture is filtered. The solid is purified by preparative thin layer chromatography (SiO ₂ , 1: 1 hexanes / ethyl acetate) to give a white solid which is further purified by recrystallization from anhydrous EtOH to give 0.027 g (28%) of pure compound. .
[550] Method F. Synthesis of Succinimide
[551] Equimolar amounts of suitable starting diacids or anhydrides and suitable starting anilines are refluxed in a solvent (eg xylene) for about 2 to 24 hours in the presence of a catalytic amount of base (eg triethylamine). The solvent is removed in vacuo and the residue is dissolved in an organic solvent (eg EtOAc) and washed successively with an aqueous dilution base (eg NaHCO ₃ ) and an aqueous dilution acid (eg HCl) and dried (eg For example, MgSO ₄ ) to concentrate. For example, by recrystallization or chromatography on silica gel.
[552] Starting diacids and anhydrides are either commercially available or obtained through various known literature methods. For example, a method for the synthesis of 2-benzyl-3-carboxy-2-methylbutanoic acid (starting material for Example 74) is shown.
[553] A solution of 2.0 g of 2-methyl-3-phenylpropionic acid (12.2 mmol) and 2.2 g of carbonyl-diimidazole (CDI, 13.56 mmol) in 20 mL of THF was refluxed under nitrogen for 1 hour. The temperature was reduced to 50 ° C. and 1.2 ml of crotyl alcohol (14.1 mmol) was added followed by 20 mg of 4- (N, N-dimethylamino) -pyridine (DMAP). The mixture was heated at 50 ° C. for 3 hours, concentrated and purified by silica gel chromatography to afford 1.7 g of intermediate ester: trans-2-butenyl 2-benzyl-3-carboxy-2-methylbutanoate (64%). To obtain.
[554] The ester is reacted with a [3,3] sigma bond to produce subsequent intermediates. A solution of 560 mg of an intermediate ester (2.57 mmol) in THF (1 mL) at -78 ° C. under argon was mixed with lithium di-isopropylamide (LDA, 3.25 mmol, 2.5 M n-BuLi in 3 mL of THF containing 500 μL of DMPU). 1.3 mL and 0.54 mL of iPr ₂ NH, −10 ° C., 15 min) is added to a THF solution. The mixture is stirred for 30 minutes before adding a solution of 480 mg of TBSCl (3.1 mmol) in 1 ml of THF. The mixture is stirred at −78 ° C. for 30 minutes and at room temperature for 20 minutes and then heated at 60 ° C. for 10 hours. The mixture is cooled to 0 ° C., quenched with 2N HCl (5 mL) and stirred at rt for 10 h. The mixture is made basic to pH 10 with 2N NaOH and extracted with ether (5 mL). The aqueous layer was separated, acidified to pH 1 with concentrated HCl, extracted with EtOAc and concentrated to afford 500 mg (89%) of intermediate: 2-benzyl-2,3-dimethyl-4-pentenoic acid.
[555] Ozone is used to oxidize the terminal alkenes and further oxidize the resulting intermediate with chromium reagent to convert monoacid to the desired diacid. A sufficient stream of O ₃ was passed through a solution of methylene chloride (10 mL) containing 120 μl of 2-benzyl-2,3-dimethyl-4-pentenoic acid (2.29 mmol) and pyridine in MeOH (20 mL) at −78 ° C. When passed quickly at, the solution appeared light blue. The mixture is treated with 1 ml of methyl sulfide and stirred at −78 ° C. for 5 minutes. The mixture is then warmed to room temperature and concentrated, passed through a silica gel column (using 10% MeOH in CH ₂ Cl ₂ as elution solvent) and concentrated. The crude material is dissolved in 5 ml of acetone and treated with Jones reagent (16 g CrO _{3 in} 100 ml H ₂ O, 16 g concentrated H ₂ SO ₄ ) at room temperature until orange color is maintained. After addition of water (100 mL), the mixture is stirred for 1 h, washed with EtOAc and concentrated. The mixture is purified by silica gel chromatography using 3% AcOH-EtOAc to afford 300 mg (55%) of the desired diacid.
[556] The compounds shown in Table 6 are prepared via this method.
[557] Examples of Compounds Synthesized by Method F
[558]
[559]
[560] Method F is illustrated by the synthesis of the compounds of Examples 92 and 93 (see Table 6), as follows: the isomers of the starting diacids of Example 92 (0.58 g, 1.8 mmol, isomers) in xylene (5 mL). 3: 1 mixture), 3,5-dichloroaniline (0.35 g, 2.2 mmol), and a mixture of Et ₃ N (10 mL, 0.07 mmol) were placed in an argon flask equipped with a Dean-Stark trap. Reflux for 24 hours. The mixture was cooled, concentrated and purified by silica gel chromatography to give 0.45 g (52%) of trans-methyl isomer (Example 73, melting point 139-140 ° C.) and cis-methyl isomer (Example 72, melting point = oil) 15 MG (2%) is obtained.
[561] Method G. Conversion of Carbonyl to Thiocarbonyl
[562] Some reagents capable of converting carbonyl to thiocarbonyl are known in the literature. Typical examples include heating the substrate for 1 to 48 hours using a reagent such as P ₂ S ₃ in a high boiling solvent such as tetralin. Separation of the product follows relatively standard conditions such as dilution of the mixture with an organic solvent such as EtOAc and washing of the mixture with water and saturated aqueous NaCl, followed by drying and concentration. Purification by silica gel chromatography or recrystallization yields the desired product.
[563] The compounds shown in Table 7 are prepared via this conventional method.
[564] Examples of Compounds Synthesized by Method G
[565] Method G is exemplified by the synthesis of the compound of Example 78 and is carried out as follows: The starting substrate (1.5 g, 3.5 mmol) is dissolved in 5 ml of tetralin and P ₂ S ₃ (0.9 g, 5.7 mmol) Treatment and heated to 225 ° C. for 2 hours. Upon cooling, the mixture is diluted with water and the product is extracted with EtOAc. The organic layer is washed with saturated aqueous NaCl, dried and concentrated. The residual oil is triturated with hexane to give a yellow solid which is separated by filtration. The material is further purified by flash chromatography (1: 4 EtOAc: hexanes) to yield 1.13 g (70%) of the desired compound.
[566] Method H. Selective Hydrolysis of Thio-Carbonyl to Carbonyl
[567] Dithio-carbonyl containing compounds prepared via Method G are hydrolyzed into each of the two monothio-carbonyl compounds according to the selection conditions. Generally at the 4 position of the ring thio-carbonyl is more sensitive to nucleophilic conditions. As shown in Example 81, it can be converted to 4-oxo-species by treatment with aqueous ethanolamine followed by acid hydrolysis. Thio-carbonyl at the 2 position of the ring is more susceptible to sulfur and can be alkylated with methyl sulfate. The intermediate can then be hydrolyzed with the appropriate acid. This affords the compound of Example 80. All classes of compounds are readily purified by silica gel chromatography or recrystallization.
[568] The compounds shown in Table 8 are prepared via this conventional method.
[569] Examples of Compounds Synthesized by Method H
[570] Example 80 is prepared by treating a solution of starting material (0.23 g, 0.49 mmol) in 3 ml of aqueous THF with 10 ml of 50% aqueous ethanolamine and heating under reflux for 2 hours. Upon cooling, the mixture is extracted with EtOAc and the organic layer is washed with water and saturated aqueous NaCl, dried and concentrated to give a brown solid. This solid is then treated with 20 ml of 6N HCl and heated at reflux for 72 hours. Upon cooling, the mixture is extracted with EtOAc and the organic layer is washed with saturated aqueous NaCl, dried and concentrated. The product is purified by preparative TLC on silica gel using 1: 1 EtOAc: hexane as solvent to give the product in 34% yield.
[571] Example 81 is prepared by treating with a solution of starting material (0.5 g, 1.09 mmol) in 1.6 mL of 2N NaOH. Since the compound does not initially dissolve, add 1 ml of water and 1 ml of THF to help dissolve. The mixture is then cooled in an ice bath and Me ₂ SO ₄ (0.12 mL, 1.3 mmol) is added dropwise over 5 minutes. The mixture is stirred for an additional 3 hours at 0 ° C. and for 45 minutes at room temperature. The reaction is quenched by the sufficient addition of 1N HCl needed to reduce the pH of the solution to 2. The mixture is extracted with EtOAc and the organic layer is washed with saturated aqueous NaCl, dried and concentrated to give a yellow oil. The oil is then treated with 10 ml of 6N HCl and heated at reflux for 3 hours. Upon cooling, the mixture is extracted with EtOAc and the organic layer is washed with saturated aqueous NaCl, dried and concentrated. The product is purified by column chromatography on silica gel using 1: 1 EtOAc: hexane as solvent to give the product in 5% yield.
[572] Method I. N-alkylation of Hydantoin
[573] Suitable hydantoin is dissolved in an aprotic solvent (eg DMF, THF or DMSO) and treated with 1 equivalent of base (eg NaH, LDA, LiHMDS, KHMDS, KH or NaHMDS). After about 10 minutes to 1 hour, a suitable alkylating agent is added and the mixture is stirred at about room temperature to 90 ° C. for up to about 24 hours. (The reaction process can be observed using TLC). The solution is then cooled and diluted with an organic solvent (eg EtOAc or CH ₂ Cl ₂ ). The organic phase is washed successively with dilute acid (eg 1N HCl) and water, dried (eg in MgSO ₄ ) and concentrated. The desired hydantoin is purified by silica gel chromatography or recrystallization.
[574] The compounds shown in Table 9 are prepared via this conventional method.
[575] Examples of Compounds Synthesized by Method I
[576]
[577]
[578]
[579]
[580]
[581]
[582]
[583]
[584]
[585]
[586]
[587]
[588]
[589]
[590]
[591]
[592]
[593]
[594]
[595]
[596]
[597]
[598]
[599]
[600]
[601]
[602]
[603] Method I is illustrated by the synthesis of the compounds of Example 97 (see Table 9), which dissolves the starting material (0.21 g, 0.5 mmol) in DMF (5 mL) and the solution is 1 M NaHMDS (0.5 mL, 0.5 mmol). It is carried out by successive treatment with a solution of and EtI (0.04 mL, 0.5 mmol). After 1 h, the reaction mixture is partitioned between EtOAc and water and the organic phase is washed with water and dried over MgSO ₄ . Column chromatography on silica gel yields 0.17 g (72%) of the desired product.
[604] Method J. C-alkylation of Heterocycle
[605] Suitable heterocycles are dissolved in an aprotic solvent (eg DMF, THF or DMSO) and treated with about 1 equivalent of base (eg Et ₃ N, LDA, KHMDS, LiHMDS or NaHMDS) at about −78 ° C. to room temperature. do. After about 10 minutes to 2 hours, a suitable alkylating agent is added and the mixture is stirred at 0-90 ° C. for up to about 24 hours. (The reaction process can be observed using TLC). The solution is then cooled and diluted with an organic solvent (eg EtOAc). The organic phase is washed successively with dilute acid (eg 1N HCl) and water, dried (eg in MgSO ₄ ) and concentrated. The desired hydantoin is purified by silica gel chromatography or recrystallization.
[606] The compounds shown in Table 10 are prepared via this conventional method.
[607] Examples of Compounds Synthesized by Method J
[608]
[609]
[610]
[611]
[612]
[613]
[614]
[615]
[616]
[617]
[618]
[619]
[620]
[621]
[622]
[623]
[624]
[625] Method J is illustrated by the synthesis of the compounds of Example 148 (see Table 10) and is carried out as follows. Starting material (0.11 g, 0.40 mmol) is dissolved in THF (5.0 mL) and cooled in an anhydrous-ice / acetone bath (about −78 ° C.). Lithium bis (trimethylsilyl) amide (LiHMDS, 405.0 μl, 0.40 mmol) is added dropwise. The resulting yellow solution is stirred in a cold bath for 15 minutes, at which time 2-fluorobenzyl bromide is added thereto. The mixture is stirred for an additional 30 minutes at this temperature followed by 30 minutes at 0 ° C. The reaction mixture is then poured into 1N HCl (40 mL) and extracted with EtOAc (50 mL). The organic layer was dried over saturated aqueous NaCl (35 mL) (Na ₂ SO ₄ ), filtered and concentrated in vacuo to afford 0.16 g of crude product. The material was purified by flash chromatography on silica gel (1: 3 EtOAc / hexanes) to yield 0.87 g (57.0%) of the compound of Example 148.
[626] Method K. C-alkylation of Hydantoin with Methyl Magnesium Carbonate
[627] Reported by Pinkbiner [J. Org. Chem. 1965, 30, 3414, hydantoin can be C-alkylated with alkyl halides using magnesium methyl carbonate (MMC). The MMC solution in an organic solvent (eg DMF) is saturated at about 80 ° C. with CO ₂ over about 1 hour. Suitable hydantoin is then added and heated with MMC for about 1 to 2 hours, at which time a suitable alkyl halide is added. The reaction mixture is then warmed to about 110 ° C. for about 2-3 hours and then cooled to about room temperature. The mixture is then poured into concentrated aqueous acid (e.g. HCl) on ice and cooled. The solid formed is recovered by filtration and purified by silica gel chromatography and / or recrystallization to give the desired product.
[628] The compounds shown in Table 11 are prepared via this method.
[629] Examples of Compounds Synthesized by Method K
[630] Method K is illustrated by the synthesis of the compounds of Example 181 (see Table 11) and is carried out as follows: The wet two-neck round bottom flask is emptied and charged with a CO ₂ atmosphere. Magnesium methyl carbonate in DMF (860 μl, 2.0 M) is added to the flask and the solution is heated to 80 ° C. CO ₂ is introduced into the dry ice-ice vessel through a cannula connected to the reaction vessel and foamed through the solution for 1.0 hour, at which time the argon line is attached and the cannula is removed. Starting material (0.21 g, 0.86 mmol) in DMF (4.0 mL) was added and the reaction mixture was heated at 80 ° C. for 1.5 h. Then a solution of 3-picolinyl chloride (0.12 g, 0.94 mmol-HCl salt is first free-based with NaOH) in DMF (1.0 mL) is added dropwise. The temperature of the oil bath is increased to 110 ° C. and the mixture is heated at this temperature for 4.0 hours. While cooling to room temperature the mixture is poured into 5 ml of a mixture of concentrated HCl and 10 g of ice and stored overnight in the refrigerator. The solution is then neutralized with 6N NaOH to pH 7-8 and the resulting solid is recovered by suction filtration and washed with ice water. The compound is dried under vacuum at 50 ° C. to give 0.20 g of crude product. This was purified by flash chromatography (5% MeOH / CH ₂ Cl ₂ ) to afford 0.06 g of material and further purified by recrystallization with EtOH to afford 0.04 g (14.9%) of compound of Example 181.
[631] Method L. Synthesis of Compound Using Pd Catalyzed Crosslinking
[632] Aryl halide or aryl triflate or catalytic amount of suitably substituted arylboronic acid or arylstanan in a suitable solvent system (e.g., ethanol and benzene containing aqueous Na ₂ CO ₃ , DMF, NMP or THF) Mix with tetrakis (triphenylphosphine) palladium. For example, other ingredients such as LiCl and triethylamine can be added if necessary. The mixture is heated at about 50 to 150 ° C. for about 2 to 48 hours. The mixture is then cooled and diluted with an organic solvent (eg EtOAc). The organic phase is washed successively with water and saturated aqueous NaCl, dried (using Na ₂ SO ₄ ) and concentrated to give a cloudy mixture from which the desired material is separated using silica gel chromatography.
[633] The compounds shown in Table 12 are prepared via this method.
[634] Examples of Compounds Synthesized by Method L
[635]
[636]
[637]
[638]
[639]
[640]
[641]
[642]
[643]
[644]
[645]
[646]
[647]
[648]
[649]
[650]
[651] Method L is illustrated by the synthesis of the compounds of Example 182 (see Table 12) and performed as follows. See Miyaura, M; Yanagi, T; Suzuki, A. Synth. Commun. 1981, 11, 513, starting materials (0.24 g, 0.54 mmol) were added to phenylboric acid (0.73 g, 0.60 mmol), tetrakis (triphenylphosphine) palladium (0) (0.31 g, 0.03 mmol). ), Sodium carbonate (0.19 g, 1.79 mmol), benzene (3.0 mL), water (1.0 mL) and ethanol (1.0 mL) and stirred under reflux for 12 h. The reaction mixture is then poured into EtOAc (70 mL) and washed successively with water and saturated aqueous NaCl. The organic layer is dried (Na ₂ SO ₄ ), filtered and concentrated in vacuo to afford 0.25 g of crude product. The material was purified by two successive silica gel chromatography columns (1: 3 followed by 1: 1 EtOAc / hexanes) to yield 0.11 g (48%) of the compound of Example 183.
[652] Method M. Synthesis of Compound Using Carbonyl Pd Catalyzed Crosslinking
[653] A suitably substituted arylboronic acid or arylstanan is substituted for aryl halides or aryl triflate and catalytic amounts of tetrakis in a suitable solvent system (e.g. ethanol and aqueous Na ₂ CO ₃ , DMF, NMP or THF) under an atmosphere of carbon monoxide. Triphenylphosphine) palladium. For example, other ingredients such as LiCl and triethylamine can be added if necessary. The mixture is heated at about 50 to 150 ° C. for about 2 to 48 hours. The mixture is then cooled and diluted with an organic solvent (eg EtOAc). The organic phase is washed successively with water and saturated aqueous NaCl, dried (using Na ₂ SO ₄ ) and concentrated to give a cloudy mixture from which the desired material is separated using silica gel chromatography.
[654] The compounds shown in Table 13 are prepared via this method.
[655] Examples of Compounds Synthesized by Method K
[656] Method M is illustrated by the synthesis of the compound of Example 215 and is carried out as follows: Starting material (0.23 g, 0.53 mmol) was added phenyltributylstannan (0.86 mL, 2.64 mmol), bis-triphenylphosphine. -Mixed with palladium (II) chloride (0.037 g, 0.05 mmol), DMF (10.0 mL) and LiCl (5.1 mg, 1.6 mmol), then the reaction mixture was purged with argon, charged with CO and charged at 115 ° C. for 12 h. Stir. The reaction mixture is then poured into 1M tetrabutylammonium fluoride (10 mL), diluted with 95 mL EtOAc and washed successively with water and saturated aqueous NaCl. The organic layer is dried (Na ₂ SO ₄ ), filtered and concentrated in vacuo to give 1.2 g of crude product. The material was purified by silica gel chromatography (1: 3 EtOAc / hexanes) to yield 0.14 g (48%) of the compound of Example 215.
[657] Method N. Electrophilic Aromatic Substitution
[658] Compounds containing aromatic rings can be modified with various reagents through electrophilic aromatic substitution. This includes techniques for acylation, nitration, sulfonation and halogenation of such rings.
[659] The compounds shown in Table 14 are prepared via this method.
[660] Examples of Compounds Synthesized by Method N
[661] The compound of Example 217 is this case and prepared by the following process. A solution of starting material (0.4 g, 1.1 mmol) in 1 mL HOAc and 0.1 mL H ₂ SO ₄ is treated with NaIO ₃ (0.05 g, 0.2 mmol) and I ₂ (0.06 g, 0.5 mmol). The mixture is then heated at 70 ° C. for 19 h, then cooled to ambient temperature and extracted several times with EtOAc. EtOAc is concentrated and the product is separated after purification by silica gel chromatography. Yield: 33 mg (30%).
[662] Method O. Deprotection of compounds protected with acid-labile groups
[663] Compounds having acid-labile protecting groups can be deprotected by treatment under acidic conditions in a known in situ manner. Generally this involves treating the substrate with TFA, cation exchange resin (H +), HCl or HBr in AcOH, with or without heating. The compound thus formed is recovered by filtration or extraction and purified by silica gel chromatography or recrystallization to give the desired product.
[664] The compounds shown in Table 15 are prepared via this conventional method.
[665] Examples of Compounds Synthesized by Method O
[666]
[667]
[668]
[669]
[670]
[671]
[672]
[673]
[674]
[675] Method O is illustrated by the synthesis of the compound of Example 219, which is carried out as follows. A stirred solution of starting material (0.10 g, 0.19 mmol) in 10 mL of methylene chloride is cooled to 0 ° C. before adding 2.0 mL of trifluoroacetic acid. Stirred continuously at 0 ° C. for 20 minutes and then allowed to slowly warm the solution to ambient temperature. The solution is stirred for an additional 6 hours, whereupon it is concentrated to yield an off-white solid which is further dried under vacuum for 16 hours. The crude solid is then triturated with 10 ml of boiling hexane and the mixture is allowed to cool to ambient temperature. The resulting white precipitate is recovered by filtration, washed with 5 ml of hexane and dried under high vacuum for 4 hours to afford 0.06 g (68% yield) of the compound of Example 219.
[676] Method P. Saponification of esters with acids using hydroxides
[677] Certain compounds with carboxylic acid esters can be converted to carboxylic acids by treatment with a saponifier in a known in situ manner. In general, this involves treating the substrate with NaOH, KOH or LiOH in a solvent such as H ₂ O which occasionally contains a solubilizer such as THF. Purification generally involves extraction of the unreacted starting material with an organic solvent such as EtOAc or CH ₂ Cl ₂ , purification of the acid by acidification of the aqueous layer and filtration or extraction with an organic solvent such as EtOAc or CH ₂ Cl ₂ . . Further purification using recrystallization, silica gel chromatography or reversible phase HPLC can give the desired product.
[678] The compounds shown in Table 16 are prepared via this conventional method.
[679] Examples of Compounds Synthesized by Method P
[680] Example 239 (Table 16) dissolves starting material (0.38 g, 0.65 mmol) in 8 mL of MeOH containing 4 mL H ₂ O and LiOH (0.08 g, 1.95 mmol) and heat the mixture at 60 ° C. for 2.5 h. It is prepared by making. MeOH is removed by concentration and the aqueous residue is treated with 1N HCl. The product is extracted with EtOAc and crystallized therefrom upon cooling. Yield 262 mg (72%).
[681] Method Q. Degradation of Phthalimide Protection Group
[682] Primary amines can be protected as their phthalimide derivatives. Such derivatives are rapidly synthesized via method U using the potassium salt of phthalimide as nucleophile. The amine can be liberated from the phthalimide protecting group using a nucleophilic reagent such as hydrazine or methyl amine in a solvent such as EtOH. Purification generally involves acidification of the aqueous layer and extraction of unreacted starting material using an organic solvent such as EtOAc or CH ₂ Cl ₂ . The free base of the amine is prepared via basicization of the aqueous layer and purified by filtration or extraction with an organic solvent such as EtOAc or CH ₂ Cl ₂ . Further purification using recrystallization, silica gel chromatography or reversible phase HPLC can give the desired product.
[683] The compounds shown in Table 17 are prepared via this conventional method.
[684] Examples of Compounds Synthesized by Method Q
[685] The compound of Example 240 is prepared by dissolving the starting material (prepared via Method U, 0.72 g, 1.2 mmol) in 73 ml of EtOH and treating it with 19.5 ml of a 33% solution of MeNH _{2 in} EtOH. The mixture is heated at reflux for 2.5 h and then cooled to ambient temperature. The reaction mixture is concentrated and the residue is dissolved in CH ₂ Cl ₂ and further washed with H ₂ O and saturated aqueous NaCl. The organic layer is dried (Mg ₂ SO ₄ ) and concentrated. The yellow oil is dissolved in EtOH and treated with HCl gas. Amine hydrochloride of the compound of Example 240 is obtained in 69% yield (0.49 g).
[686] Method R. Conversion of Nitrile to Amidine
[687] Aromatic nitriles can be converted to amidine groups by several methods. This conversion generally requires a two step process in which the first step involves treatment with an acid (eg HCl) and an alcohol (eg MeOH or EtOH) to produce an intermediate imino ether. The derivative is then converted to amidine by treatment with an amine. It is generally purified by recrystallization of derivative salts of amidines. Further purification using recrystallization, silica gel chromatography or reversible phase HPLC can give the desired product.
[688] The compounds shown in Table 18 are prepared via this conventional method.
[689] Examples of Compounds Synthesized by Method R
[690] The compound of Example 243 is prepared by dissolving the starting material (0.2 g, 0.4 mmol) in 7 ml of EtOH, cooling the mixture in an ice bath and treating the mixture with anhydrous HCl gas for 15 minutes. The mixture is stirred at rt for 1 h and concentrated to afford crude imino ether hydrochloride. The intermediate is dissolved in EtOH (10 mL), cooled in an ice bath and treated with anhydrous NH ₃ gas for 20 minutes. After 5 hours, the reaction mixture is concentrated to give crude amidine hydrochloride. The material was purified via silica gel chromatography (1: 9 MeOH: CH ₂ Cl ₂ ) to afford 0.08 g (38%) of product.
[691] Method S. Reduction of carboxylic acids with alcohols
[692] Certain compounds with carboxylic acids can be reduced to alcohols by treatment with a reducing agent in a known in situ manner. Generally this involves treating the substrate with a LiAlH ₄ or BH ₃ based reagent in a solvent such as THF or ether. After careful quenching with an aqueous system, purification is generally carried out with extraction and recrystallization of the product into an organic solvent such as EtOAc or CH ₂ Cl ₂ to obtain the desired product, filtration using silica gel chromatography or reversible phase HPLC. It includes.
[693] The compounds shown in Table 19 are prepared via this conventional method.
[694] Examples of Compounds Synthesized by Method S
[695] The compound of Example 244 is dissolved starting material (prepared via methods J and O, 0.16 g, 0.32 mmol) in 1 mL of THF and cooling the mixture in an ice bath which is 0.65 mL of 1M BH ₃ -THF solution (0.65 mmol). It is prepared by treatment with. Allow the mixture to warm to room temperature and stir for 15 hours. Water was added slowly and carefully to quench the reaction mixture and the organic components were extracted with EtOAc. The EtOAc layer is washed with water, saturated aqueous NaCl and dried over Na ₂ SO ₄ . Concentration and silica gel chromatography (1: 1 EtOAc: hexanes) give the desired product (0.06 g, 42%).
[696] Method T. Deprotection of Compounds with Nucleophiles
[697] Certain compounds with methoxy groups can be deprotected with hydroxy derivatives by treatment with certain nucleophiles in a known in situ manner. Generally this involves treating the substrate with BBr ₃ or TMSI in a solvent such as CH ₂ Cl ₂ and generally does not heat or cool after cooling in an ice bath. After about 10 minutes to 8 hours, the reaction is quenched with a weak base such as aqueous NaHCO ₃ and the organic components are extracted with a solvent such as EtOAc and concentrated and purified by silica gel chromatography or recrystallization to give the desired product. .
[698] The compounds shown in Table 20 are prepared via this conventional method.
[699] Examples of Compounds Synthesized by Method T
[700]
[701] Method T is exemplified by the synthesis of the compound of Example 246, and is carried out as follows. To a stirred solution of starting material in CH ₂ Cl ₂ 9㎖ (0.35g, 0.64mmol) before applying the _{BBr 3 (1.07mmol, 1M CH 2} Cl 2) 1.0㎖ cooled to 0 ℃. After stirring continuously, the solution is allowed to search warm to ambient temperature. The solution is stirred for an additional 4 hours, at which time saturated aqueous NaHCO ₃ is added and the organic layer is removed and concentrated to give the crude product. Purification by silica gel chromatography (1: 4 EtOAc: hexane) affords 0.16 g (48% yield) of the desired compound.
[702] Method U. Nucleophilic Substitution
[703] Suitable electrophiles are dissolved in an aprotic solvent (eg DMF, THF or DMSO) and nucleophiles (eg Me ₃ N, Na salt of imidazole, Na ₂ SO ₃ , NaCN, P (OEt) ₃ ) Treatment is carried out at about room temperature to 100 ° C. with 1-3 equivalents or K salt of phthalimide. The mixture is stirred at about 0-100 ° C. for up to about 24 hours. (The reaction process can be observed using TLC). The solution is then cooled and diluted with an organic solvent (eg EtOAc). The organic phase is washed successively with dilute aqueous acid (eg 1N HCl) and water, dried (eg in MgSO ₄ ) and concentrated. The desired compound is purified by silica gel chromatography, reversible phase HPLC or recrystallization.
[704] The compounds shown in Table 21 are prepared via this conventional method.
[705] Examples of Compounds Formed by Method U
[706]
[707]
[708]
[709]
[710]
[711]
[712] Method U is illustrated by the synthesis of the compound of Example 262, and is carried out as follows. To the starting material (0.28 g, 0.54 mmol) was added 1-H-pyrazolecarboxamidine (0.08 g, 0.54 mmol) followed by 7 mL of DMF and 0.2 mL of N, N-diisopropyl-ethylamine. The resulting mixture is then stirred at room temperature for 15 hours. Ether is then added to make the mixture cloudy. Since no crystal is formed, MeOH is added to redissolve the reaction components and the product is precipitated as its HCl salt by addition of 1N HCl. The solid is recovered and washed with ether to yield 0.11 g (20%) of guanidine hydrochloride.
[713] Method V. Decomposition of Enantiomeric Mixtures
[714] There are several ways to decompose the compound of the present invention into its enantiomeric pure form. One such method is chiral HPLC. An exemplary column packing is Chiracel-OD (Diacel Chemistry Industries). An exemplary solvent system is 9: 1 hexanes: iso-propyl alcohol. In general, R-enantiomers are eluted first but should not be used as sole criteria for the arrangement of stereochemistry.
[715] The compounds shown in Table 22 are prepared via this method.
[716] Examples of Compounds Obtained by Method V
[717]
[718]
[719]
[720]
[721] Explanation of Biological Properties
[722] The biological properties of representative compounds of formula I were studied by the following experimental protocol. The results of these tests are reported in Table 23 below.
[723] Assay of LFA-1 Inhibition Measurement Binding to ICAM-1
[724] Purpose of the test:
[725] This assay protocol was designed to study the antagonistic action directed at the interaction of CAM, ICAM-1 with leukointegrin CD18 / CD11a (LFA-1) by test compounds.
[726] Description of the assay protocol:
[727] LFA-1 was immunopurified from 20 g pellets of human JY or SKW3 cells using TS2 / 4 antibody using the above protocol [Dustin, MJ; et al., J. Immunol. 1992, 148, 2654-2660. LFA-1 is purified from SKW3 lysate by immunoaffinity chromatography in TS2 / 4 LFA-1 mAb Sepharose and eluted at pH 11.5 in the presence of ₂ mM MgCl ₂ and 1% octylglucoside. After collecting and neutralizing fragments from the TS2 / 4 column, the sample is collected and precleaned using Protein G agarose.
[728] Soluble forms of ICAM-1 are constructed, expressed, purified and characterized as described above. Marlin, S .; et al., Nature, 1990, 344, 70-72 and see Arruda, A .; et al., Antimicrob. Agents Chemother. 1992, 36, 1186-1192. That is, isoleucine 454, located at the putative border between domain 5 and the transmembrane domain of the ectodomain, is transformed into a stop codon using standard oligonucleotide-directed mutagenesis. This construction yields the same molecules as the first 453 amino acids of membrane-bound ICAM-1. Expression vectors, along with promoters, conjugation signals and polyadenylation signals of the SV40 initial region, are constructed with the hamster dihydrofolate reductase gene, neomycin-resistant marker and coding region of the sICAM-1 construct described above. Recombinant plasmids are transfected into CHO DUX cells using standard calcium phosphate methods. Cells pass through selective medium (G418) and colonies secreting sICAM-1 are amplified using methotrexate. sICAM-1 is purified from serum-free medium using typical non-affinity chromatography techniques, including ion exchange chromatography and size exclusion chromatography.
[729] 96-well plate of sICAM-1 in 40 μg / ml of Dulbecco phosphate buffered saline using LFA-1 binding ICAM-1 to calcium and magnesium, additionally 2 mM MgCl ₂ and 0.1 mM PMSF (dilution buffer) Observe by first incubating at room temperature for 30 minutes. The plate is then blocked by adding 2% (w / v) bovine serum albumin to 37 ° C. for 1 hour in dilution buffer. The blocking solution is removed from the wells and the test compound is diluted, then about 25 ng of immunoaffinity purified LFA-1 is added. LFA-1 is incubated at 37 ° C. for 1 hour in the presence of test compound and ICAM-1. The wells are washed three times with dilution buffer. Bound LFA-1 is detected by addition of the polyclonal antibody directed against the peptide corresponding to the CD18 cytoplasmic tail in a 1: 100 dilution with dilution buffer and 1% BSA and then incubated at 37 ° C. for 45 minutes. The wells are washed three times with dilution buffer and the bound polyclonal antibody is detected by addition of a 1: 4000 dilution of horse radish peroxidase conjugated with a goth immunoglobulin directed against the rabbit immunoglobulin. The reagents were incubated at 37 ° C. for 20 minutes, then the wells were rinsed as above and a substrate for hose radish peroxidase was added to each well, proportional to the amount of LFA-1 bound to sICAM-1. Develop a quantitative colorimetric signal. Soluble ICAM-1 (60 μg / ml) is used as a positive control for inhibiting LFA-1 / sICAM-1 interaction. Lack of addition of LFA-1 to the binding assay is used as background control for all samples. Dose-response curves are obtained for all test compounds.
[730] The results of these tests are reported as Kd (μM).
[731] MMT assay to measure cytotoxicity
[732] Purpose of the test:
[733] To obtain meaningful data from cell assays, compounds should first be tested in assays to determine cytotoxicity. The MTT assay can be used for this purpose.
[734] Description of the assay protocol:
[735] MTT, i.e. (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl-2H-tetrazolium bromide), is degraded by cells with active mitochondria to produce a dark blue / purple formazan product. It is a yellow substrate that forms. This precipitate is soluble and the amount of sample can be quantified by spectrophotometry. See Gerlier, D .; Thomasset, N. J. Immunol. Methods, 1986, 94, 57-63). The amount of tonality is proportional to the number of viable cells. This assay system is used to assess the effect of test compounds on cell viability in vitro.
[736] SKW3 expressing LFA-1 is used. Adjust the cells used for each assay to 1.25 × 10 ⁶ cells / ml and add 100 μL of this stock to each well of a 96-well flat microtiter plate. For each condition in a particular experiment, triple replicate wells are adjusted. Serial dilutions of each test compound or vehicle alone are added to each well. Cells are incubated with compounds for 4 to 24 hours at 37 ° C. before assessing cell viability. Then 10 μl of filtered sterilized MTT is added to each well. MTT stocks are prepared in phosphate buffered saline at a concentration of 5 mg / ml. The plate is then incubated for 1 hour at 37 ° C. under 5% CO ₂ atmosphere. Periodically, the plates are tested for formazan crystal color development.
[737] At the end of the incubation time, 100 μl of 0.04 N HCl in iso-propyl alcohol is added to each well to dissolve the formazan crystals. Repeat pipetting with multiple pipettes to thoroughly mix each well. The plate is left at room temperature for 15-20 minutes and then read by spectrophotometer. Absorbance is measured at a test wavelength of 570 nm. Data is recorded as concentration ranges (μM) in which 50% of the cells can no longer survive.
[738] Assay to measure inhibition of SKW3 cells binding to ICAM-1 versus binding to fibronectin
[739] Purpose of the test:
[740] This assay is used to test the selective ability of test compounds to antagonize the interaction of the cell binding forms of LFA-1 with ICAM-1. This assay uses SKW3, which can express human T cell lines and other integrins not associated with CD18, CD11a and CD18, CD11a and can be “activated” by phorbol esters. Phorbol esters enhance the affinity of CD18, CD11a for ICAM-1.
[741] The same lymphocyte, SKW3, is also attached to fibronectin in the presence of phorbol esters. This attachment is mediated by membrane proteins independent of LFA-1 / ICAM-1 interactions. SKW3 cells express another integrin, VLA4, which is a receptor for fibronectin. Thus, as a preliminary indication of test compound selectivity that interferes with leucointegrin / CAM interactions but not for other integrin-ligand bonds, the ability of the compound to antagonize cell-bound fibronectin receptors during interaction with purified fibronectin. Can be tested Compounds that inhibit fibronectin adhesion are not specific antagonists of CD18, CD11a / ICAM-1 binding.
[742] Description of the assay protocol:
[743] 96 well plates are applied with sICAM-1 (40 μg / ml) or fibronectin (100 μg / ml) in dilution buffer for 1 hour at room temperature. 100 μl of properly diluted test compound or 100 μl of RPMI with 15% lethal serum as a control is added to the wells. CD18, CD11a and VLA4 [Dustin, M .; et al., J. Exp. Med. 1987, 165, 672-692] are washed and suspended at a concentration of 10 ⁶ cells / ml in RPMI with 15% lethal serum. Immediately before adding the cells to the wells, the cells are stimulated with phorbol ester 12-myristate 13-acetate (PMA) to a final concentration of 100 μg / ml. 100 μl of cells are then added to wells with a final concentration of 50 μg / ml PMA and 2 cells / well. Plates are incubated at 37 ° C. for 2 hours. Unbound or loosely bound cells are gently washed off with RPMI. Cells remaining and thereby bound to ICAM-1 or fibronectin are quantified with the same reagents used above for the MTT test.
[744] Data is recorded as concentrations or concentration ranges (μM) where binding is inhibited by 50%.
[745] Compounds That Inhibit JY Cell Aggregation
[746] Purpose of the test:
[747] This assay is an in vitro cell-to-cell adhesion assay that can be used to test the ability of a test compound to directly inhibit LFA-1 dependent aggregation at the cellular level.
[748] Many Epstein-Barr virus-transforming cells exhibit aggregation. This aggregation can be enhanced with the addition of phorbol esters. This isotypic aggregation (ie, aggregation involving only one cell type) has been found to be blocked by anti-LFA-1 antibodies. Rothlein, R. R .; et al., J. Exp. Med. 1986, 163, 1132-1149. Thus, the degree of LFA-1-dependent binding can be measured by assessing the degree of natural or phorbol ester-dependent aggregation formation.
[749] Reagents that interfere with LFA-1-dependent aggregation can be identified by using an assay that can determine whether the reagent interferes with natural or phorbol ester-dependent aggregation of Epstein-Barr virus transformed cells. Cells of JY cell lines for homologous aggregation assays (Terhost, L; et al., Proc. Natl. Acad. Sci. USA, 1976, 73, 910 may be preferred. This assay, which can measure LFA-1 dependent aggregation, can be used to identify reagents that act as antagonists for LFA-1 dependent aggregation. Such reagents can act by impairing the ability of LFA-1 or ICAM-1 to mediate aggregation. Thus, reagents can be examined to directly determine whether they are antagonists of LFA-1 aggregation.
[750] Description of the assay protocol:
[751] JY cells are cultured in RPMI 1640 culture medium supplemented with 10% lethal serum and 50 μg / ml gentamycin. Cells are incubated at 37 ° C. under 5% CO ₂ atmosphere at 95% relative humidity. JY cells used in this assay are washed twice with RPMI 1640 medium containing 5 mM HEPES buffer and resuspended at 2 × 10 ⁶ cells / ml concentration. 50 μl of test compound diluted in complete medium, 50 μl of complete medium with or without purified monoclonal antibody (negative and positive control for inhibition, respectively), 200 ng / of phorbol ester phorbol myristate acetate (PMA) 50 μl of complete medium containing 100 ml and 100 μl of cells at a concentration of 2 × 10 ⁵ cells / ml in complete medium are added to a flat 96-well microtiter plate. The final concentrations resulting are 50ng / ml PMA and 2 × 10 ⁵ cells / well. The cells are allowed to anchor naturally and the extent of aggregation is measured at various time points. The score ranges from 0 to 4, wherein 0 indicates that virtually no cells are present; 1 indicates that less than 25% of the cells are clumped; 2 indicates that less than 50% of the cells are clumped; 3 indicates that less than 75% of the cells are clumped; 4 indicates that the cells are 100% aggregated. Such methods are described in Rothlein, RR; et al., J. Exp. Med. 1986, 163, 1132-1149. This document also reports that antibodies against LFA-1 can inhibit aggregation formation. The document adds that 100% of cells form aggregates in the absence of LFA-1 antibodies, while less than 20% of cells are found to be aggregates when an anti-LFA-1 antibody is added.
[752] Data is recorded as concentrations or concentration ranges (μM) that inhibit binding by 50%.
[753] Assay for Determining Mixed Lymphocyte Response
[754] Purpose of the test:
[755] As noted above, ICAM-1 is required for effective cell interaction during immune responses mediated through LFA-1-dependent cell adhesion. When lymphocytes from two unrelated individuals are incubated together, subcellular transformation and cell proliferation of lymphocytes are observed. This response is known as a mixed lymphocyte response (MLR) and is similar to the response of lymphocytes to the addition of antigen or mitogen. Immunology: The Science of Self-Nonself Discrimination; Klein, J., Ed .; John Wiley & Sons: NY, 1982, pp 453-458. Monoclonal antibodies directed against ICAM-1 and LFA-1 are used as controls to demonstrate inhibition of cell adhesion-dependent lymphocyte stimulation and proliferation.
[756] This assay protocol is used to determine the effect of test compounds on human MLR. The ability of test compounds to inhibit MLR and antigen-specific mononuclear cell responses shows that the test compounds have therapeutic uses in acute graft rejection as well as related immune mediated disorders following CD18, CD11a / ICAM interactions.
[757] Description of the assay protocol:
[758] Peripheral blood is obtained from a conventional healthy donor by venipuncture. Blood is collected into heparinized tubes and diluted 1: 1 at room temperature using Puck G (GIBCO) balanced salt solution (BSS). The blood mixture (20 ml) is layered in 15 ml Ficoll / Hypaque density gradient (Pharmacia, density = 1.078, room temperature) and centrifuged at 1000 × g for 20 minutes. The surface is then collected and washed three times with Puck G. Count the cells with a hemocytometer and RPMI 1640 culture medium (GIBCO) containing 0.5% gentamicin, 1 mM L-glutamine (GIBCO) and 5% heat inactivation (56 ° C., 30 minutes) human AB serum (Flow Laboratories) Resuspended (hereafter referred to as RPMI-culture medium).
[759] Peripheral blood mononuclear cells (PBMCs) are incubated in medium at 6.25 × 10 ⁵ cells / ml in Leanbro microtiter plates. Stimulator cells from individual donors (cells that cannot be proliferated by radiation treatment) are incubated with the responder cells at the same concentration. Test compounds are added to the wells at various concentrations. The total dose per medium is 0.2 ml. Controls include compound vehicle alone (DMSO), responder cells alone, and stimulator cells alone. The culture plate is incubated at 37 ° C. in 5% CO ₂ -humidified atmosphere for 5 days. Wells are stimulated with 0.5 μCi of tritiated thymidine ( ³ HT) (New England Nuclear) for the last 18 hours of incubation. In some cases a two stage MLR may be performed. The protocol is the same except that the cells of the second donor are not inactivated by radiation.
[760] Cells are collected with a glass fiber filter using an automated multiple sample collector (Skatron, Norway) and washed with water and methanol. The filter is oven dried and counted in aquasol in a Beckman (LS-3801) liquid scintillation counter.
[761] Data is recorded as "+" or "-" at the given concentration (μM).
[762] In vivo: allogeneic cell transplant model
[763] Purpose of the test:
[764] The ability of a cell to recognize another cell from itself or another genetically different entity (not itself) is an important property in maintaining the integrity of tissue and organ structure. Allogeneic cell transplant responses are an important model for the study of transplant rejection and immunocompatibility. This T-cell-mediated immune response can be elicited by infusion of lymphocytes from a tissue incompatible mouse species into a footpad in adult mice. This response is characterized by T-cell proliferation limited to the supine lymph node receiving drainage from the injected footpad site. No in vitro system can fully replicate this in vivo response. Thus, such animal models can be used to assess the ability of test compounds to inhibit transplant rejection.
[765] Description of the assay protocol:
[766] Experiments are performed using male or female mice (20-26 g). All histocompatibility mouse strains are sufficient for the donor and recipient population. Typically DBA mice are used as donors and C57bl / 6 mice are used as recipients. A stabilization and conditioning period of at least one week is required before use for the time that the animal is maintained in accordance with the Animal Resource Center SOP. In each study 36 recipient mice were used in six groups. The test lasts about four days. Donor mice are CO ₂ choked to remove the spleen and make a cell suspension. Cells (1.0 × 10 ⁷ / vertebral in 0.05 ml) are injected intradermally (according to standard protocol) into the back ulnar skin of recipient mice. After 4 days, animals are suffocated with CO ₂ to remove the knee node and weigh. Groups of mice receiving putative immunosuppressants are subcutaneously, intraperitoneally or orally administered daily 1 hour prior to cell infusion and following the standard protocol. Student's T-test is used to determine significant differences between the supine lymph node of mice treated with putative immunosuppressive agents and the group of treated mice [Kroczek, RA; Black, CDV; Barbet, J .; Shevach, EM, J. Immunology, 1987, 139, 3597].
[767] Data is reported as the dose at which 50% inhibition is observed and how the test compound is administered. In Table 23, the following description is applicable:^and = not measured;^bInhibition at 160 μg / ml;^cNo inhibition was observed below the highest dose. Accurate Quantification Not always possible due to the inherent toxicity of the compound (see MTT results);^dInhibition rate (concentration μM);^eApproximation from incomplete dose-response curves;^fNot measured; The compound is a synthetic intermediate.
[768]
[769]
[770]
[771]
[772]
[773]
[774]
[775] Description of Therapeutic Uses
[776] New and known small molecule compounds used in the methods according to the invention inhibit ICAM-1 / LFA-1 dependent homozygous aggregation of human lymphocytes, human lymphocyte adhesion to ICAM-1 and human lymphocyte responses to antigens. The compounds have therapeutic uses in immune cell activation / proliferation as competitive inhibitors of intercellular ligand / receptor binding responses, including, for example, CAMs and leucointegrin. Inflammatory conditions that can be treated with the compounds included in the present invention are those caused by nonspecific immune system responses in mammals (eg, secondary multiple organ damage syndrome, trauma to adult respiratory distress syndrome, shock, oxygen toxicity, pneumonia, trauma). Secondary multiple organ injury syndrome, systemic perfusion disease due to cardiopulmonary bypass, the use of myocardial infarction or thrombolytic agents, acute glomerulonephritis, vasculitis, reactive arthritis, skin diseases with acute inflammatory factors, seizures, burns, hemodialysis , Leukopenia transfusion, ulcerative colitis, necrotizing colitis and granulocyte transfusion related syndromes) and conditions due to specific immune system responses in mammals (eg, psoriasis, organ / tissue transplant rejection, Raynaud's syndrome) Graft-versus-host reactions and autoimmune diseases including, autoimmune thyroiditis, dermatitis, multiple sclerosis, rheumatoid arthritis, phosphorus It includes dependent diabetes mellitus, uveitis, Crohn's (Crohn) inflammatory bowel disease and ulcerative colitis, and systemic lupus erythematosus, including diseases) - Lin. In accordance with the present invention, these new and known compounds can also be used for the treatment of asthma or as additives that minimize toxicity with cytokine treatment in the treatment of cancer. In general, the compounds can be used in the treatment of diseases currently treatable through steroid treatment.
[777] According to the methods provided by the present invention, such novel and known compounds may be administered alone or in combination with other immunosuppressive or anti-inflammatory agents for the purpose of "prevention" or "treatment". When provided for prophylaxis, the immunosuppressive compound (s) are given prior to any inflammatory response or indication (eg, before or immediately after organ or tissue transplantation or prior to all organ rejection signs). Prophylactic administration of a compound of formula (I) prevents or attenuates any subsequent inflammatory response (eg, rejection of an implanted organ or tissue). Therapeutic administration of a compound of formula (I) attenuates all actual inflammation (eg, rejection of transplanted organs or tissues). Thus, according to the invention, the compounds of formula (I) can be administered before the onset of inflammation (to the extent that inhibiting the expected inflammation) or after the onset of inflammation.
[778] The new and known compounds of formula (I) according to the invention can be administered orally, parenterally or topically in single or divided doses. Suitable oral dosages for the compounds of formula (I) may range from about 0.5 mg to 1 g per day. In parenteral preparations, suitable dosage units may contain 0.1 to 250 mg of the compound, whereas for topical treatment, preparations containing 0.01 to 1% of the active ingredient are preferred. However, the dosage between patients may vary, and that the dosage for a particular patient may depend on the physician's judgment of the patient's physique and condition as well as the patient's drug response as a criterion for determining the appropriate dosage. Keep in mind.
[779] When orally administered a compound of the present invention, it may be administered as a medicament in the form of a pharmaceutically formulation containing a compound associated with an acceptable pharmaceutical carrier material. Such carrier material may be an inert organic or inorganic carrier material suitable for oral administration. Examples of such carrier materials are water, gelatin, talc, starch, magnesium stearate, gum arabic, vegetable oils, polyalkylene-glycols, petroleum jelly and the like.
[780] Pharmaceutical formulations can be prepared by conventional methods and the final dosage form can be, for example, a solid dosage form such as a tablet, dragee, capsule, or the like or a liquid dosage form such as a solution, suspension, emulsion or the like. Pharmaceutical formulations can be applied to conventional pharmaceutical treatments such as sterilization. In addition, pharmaceutical preparations may contain conventional adjuvants such as preservatives, stabilizers, emulsions, flavor-enhancing agents, wetting agents, buffers, salts for varying osmotic pressure, and the like. Solid carrier materials that can be used include, for example, starch, lactose, mannitol, methyl cellulose, microcrystalline cellulose, talc, silica, dibasic calcium phosphate and high molecular weight polymers (eg polyethylene glycol).
[781] For parenteral use, the compounds of formula (I) may contain, along with blood, thickeners, suspensions or other pharmaceutically acceptable additives, antibacterial agents, antioxidants, preservatives, buffers, or other solutes that form isotonic solutions. Can be administered as an aqueous or non-aqueous solution, suspension or emulsion in an acceptable oil or interliquid mixture. Additives of this type are, for example, tartrate, citrate and acetate buffers, ethanol, propylene glycol, polyethylene glycols, complexing agents (e.g. EDTA), antioxidants (e.g. sodium bisulfite, sodium meta Bisulfite and ascorbic acid), high molecular weight polymers for viscosity control (e.g. liquid polyethylene oxide) and polyethylene derivatives of sorbitol anhydride. If desired, preservatives such as benzoic acid, methyl or propyl parabens, benzalkonium chloride and other quaternary ammonium compounds can also be added.
[782] The compounds of the present invention may also be administered as solutions for nasal applications and may contain, in addition to the compounds of the present invention, suitable buffers, tension modifiers, microbial preservatives, antioxidants and viscosity enhancing agents in aqueous vehicles. Examples of agents used to increase the viscosity are polyvinyl alcohol, cellulose derivatives, polyvinylpyrrolidone, polysorbate or glycerin. The microbial preservative to be added may include benzalkonium chloride, thimerosal, chloro-butanol or phenylethyl alcohol. In addition, the compounds provided by the present invention can also be administered as suppositories.
[783] Formulation
[784] Compounds of formula (I) can be prepared in a variety of ways for therapeutic administration.
[785] Example A
[786] Capsule or tablet
[787] Example A-1 Example A-2 ingredient amount ingredient amount Compound of formula (I) 250 mg Compound of formula (I) 50 mg Starch 160mg Dicalcium phosphate 160mg Microcrystalline cellulose 90 mg Microcrystalline cellulose 90 mg Sodium starch glycolate 10mg Stearic acid 5mg Magnesium stearate 2mg Sodium starch glycolate 10mg Haze Colloidal Silica 1mg Haze Colloidal Silica 1mg
[788] The compound of formula (I) is mixed in a powder mixture with the premixed excipient material as identified above except for the lubricant. The lubricant is then mixed and the resulting mixture is compressed into tablets or totally hard gelatine capsules.
[789] Example B
[790] Parenteral solution
[791] ingredient amount Compound of formula (I) 500 mg PEG 400 40 capacity% Ethyl alcohol 5% by volume Saline 55% by volume
[792] The excipient materials are mixed and then added to one of the compounds of formula (I) in the capacity necessary for dissolution. Continue mixing until the solution is clear. The solution is then filtered into a suitable container or ampoule and autoclaved to sterilize.
[793] Example C
[794] Suspension
[795] ingredient amount Compound of formula (I) 100mg Citric acid 1.92 g Benzalkonium chloride 0.025% by weight EDTA 0.1 wt% Polyvinyl alcohol 10% by weight water Appropriate amount up to 100ml
[796] The excipient material is mixed with water, then one of the compounds of formula (I) is added and mixing is continued until the suspension is homogeneous. The suspension is then transferred to a suitable container or ampoule.

权利要求:
Claims (17)
[1" claim-type="Currently amended] A method for treating or preventing an inflammatory or immune cell-mediated disease or condition comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof in a prophylactic or therapeutic amount.
Formula I

In the above formula,
Y is oxygen or sulfur atom,
Z is oxygen or sulfur atom,
X is a divalent group of the formula> CHR ¹ ,> NR ¹ ,> CHSO ₂ R ¹ or> NSO ₂ R ¹ , or an oxygen or sulfur atom, wherein R ¹ is
(A) a hydrogen atom,
(B) an alkyl or cycloalkyl group is
(Iii) halogen,
(Ii) oxo,
(Iii) one or more hydrogen atoms of the aryl group are each optionally
(a) alkyl of 1 to 3 carbon atoms,
(b) -COOH,
(c) -SO ₂ OH,
(d) -PO (OH) ₂ ,
(e) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(f) R ⁸ and R ⁹ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or R ⁸ and R ⁹ are nitrogen atoms in between; A group of formula -NR ⁸ R ⁹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together form a heterocyclic ring;
(g) R ¹⁰ and R ¹¹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁰ and R ¹¹ together with the nitrogen atom therebetween form a heterocyclic ring A group of formula -CONR ¹⁰ R ¹¹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
(h) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(i) a group of formula -SR ^12b wherein R ^12b is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(j) cyano, or
(k) R ¹³ , R ¹⁴ and R ¹⁵ are each independently a hydrogen atom or alkyl of 1 to 3 carbon atoms, and two of R ¹³ , R ¹⁴ and R ¹⁵ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Phenyl, naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, which may be substituted by an amidino group of Isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, triazinyl, indolinyl, isoindoleyl, benzo [b] furanyl, benzo [b] thiophenyl, indazolyl, Consisting of benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, furinyl, quinolininyl, cinnolinyl, phthalanyl, quinoxalinyl, naphthyridinyl, pterridinyl and quinazolinyl Aryl selected from the class,
(Iii) a group of formula -COOR ¹⁶ wherein R ¹⁶ is straight or branched chain alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
(Iii) cyano,
(Iii) R ¹⁷ and R ¹⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁷ and R ¹⁸ together with the nitrogen atom therebetween form a heterocyclic ring; A group of formula -CONR ¹⁷ R ¹⁸ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
(Iii) a group of formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(Iii) a group of formula -SR ²⁰ wherein R ²⁰ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(Iii) R ²¹ and R ²² are each independently
(a) a hydrogen atom,
(b) alkyl or acyl or cycloalkyl of 3 to 7 carbon atoms,
(c) a group of the formula-(CH ₂ ) _m COOH, wherein m is 0, 1 or 2, or
(d) a group of the formula-(CH ₂ ) _n COOR ²³ , wherein n is 0, 1 or 2 and R ²³ is straight or branched chain alkyl of 1 to 6 carbon atoms, or R ²¹ and R ²² are between A group of formula -NR ²¹ R ²² constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of
(Iii) chemical formula Wherein R ²⁴ , R ²⁵ and R ²⁶ are each independently a branched or straight chain alkyl group having 1 to 7 carbon atoms and Q ⁻ is a chlorine, bromine or iodine counterion. Branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
(C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
(D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
(E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
(F) chemical formula (Where r is 2, 3, 4, 5 or 6, R ²⁷ , R ²⁸ and R ²⁹ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, and 2 of R ²⁷ , R ²⁸ and R ²⁹ ) May also constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom (s) therebetween form a heterocyclic ring,
(G) chemical formula (Wherein s is 2, 3, 4, 5 or 6, R ³⁰ , R ³¹ , R ³² and R ³³ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, R ³⁰ , R ³¹ , R ³² And two of R ³³ may also constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom (s) therebetween form a heterocyclic ring;
The nitrogen atom of the (H) group optionally
(Iii) alkyl having 1 to 3 carbon atoms,
(Ii) carboxylic ester groups having 2 to 7 carbon atoms,
(Iii) a carboxylic acid group having 2 to 5 carbon atoms,
(Iii) a phosphoric acid group having 1 to 6 carbon atoms, or
(Iii) piperidyl substituted with sulfuric acid groups of 1 to 6 carbon atoms, or
(I) one or more hydrogen atoms of the aryl group are each optionally
(Iii) alkyl having 1 to 3 carbon atoms,
(Ii) -COOH,
(Iii) -SO ₂ OH,
(Iii) -PO (OH) ₂ ,
(Iii) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(Iii) R ⁸ and R ⁹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁸ and R ⁹ are nitrogen atoms in between; A group of formula -NR ⁸ R ⁹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together form a heterocyclic ring;
(Iii) R ¹⁰ and R ¹¹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁰ and R ¹¹ together with a nitrogen atom therebetween form a heterocyclic ring A group of formula -CONR ¹⁰ R ¹¹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
(Iii) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(Iii) a group of formula -SR ^12b wherein R ^12b is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(x) cyano, or
(xi) R ¹³ , R ¹⁴ and R ¹⁵ are each independently a hydrogen atom or alkyl of 1 to 3 carbon atoms, and two of R ¹³ , R ¹⁴ and R ¹⁵ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Phenyl, naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, which may be substituted by an amidino group of Isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, triazinyl, indolinyl, isoindoleyl, benzo [b] furanyl, benzo [b] thiophenyl, indazolyl, Consisting of benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, furinyl, quinolininyl, cinnolinyl, phthalanyl, quinoxalinyl, naphthyridinyl, pterridinyl and quinazolinyl Aryl selected from the class
R ² is (A) a hydrogen atom, or
(B) alkyl or cycloalkyl groups are optionally
(Iii) a group of formula -OR ³⁴ wherein R ³⁴ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
(Ii) side chains having 1 to 3 carbon atoms, each of which R ³⁵ and R ³⁶ may each independently be substituted with a group of formula —NR ³⁵ R ³⁶ wherein a hydrogen atom, alkyl having 1 to 2 carbon atoms or acyl having 1 to 2 carbon atoms; Straight chain alkyl or cycloalkyl having 3 to 5 carbon atoms,
R ³ is a group of the formula-(CR ³⁷ R ³⁸ ) _x (CR ³⁹ R ⁴⁰ ) _y R ⁴¹ , wherein
x and y are each independently 0 or 1,
R ³⁷ , R ³⁸ and R ³⁹ are each independently
(A) a hydrogen atom,
(B) a group of formula -OR ⁴² , wherein R ⁴² is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
(C) branched or straight chain alkyl of 1 to 3 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
R ⁴⁰ is (A) a hydrogen atom,
(B) a group of formula -OR ⁴² , wherein R ⁴² is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(C) branched or straight chain alkyl of 1 to 3 carbon atoms or cycloalkyl of 3 to 5 carbon atoms, or
(D) at least one hydrogen atom of the aryl group is each optionally
(Iii) one or more hydrogen atoms of the aryl group are each optionally
(a) branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(b) -COOH,
(c) -SO ₂ OH,
(d) -PO (OH) ₂ ,
(e) a group of formula -COOR ⁴⁴ wherein R ⁴⁴ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(f) R ⁴⁵ and R ⁴⁶ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁴⁵ and R ⁴⁶ being between A group of the formula -NR ⁴⁵ R ⁴⁶ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together with the nitrogen atom of form a heterocyclic ring;
(g) R ⁴⁷ and R ⁴⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁴⁷ and R ⁴⁸ together with a nitrogen atom therebetween A group of formula -CONR ⁴⁷ R ⁴⁸ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a click ring,
(h) a group of formula -OR ⁴⁹ wherein R ⁴⁹ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
(i) a group of formula -SR ⁵⁰ wherein R ⁵⁰ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
(j) cyano,
(k) nitro,
(l) R ⁵¹ , R ⁵² and R ⁵³ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, and two of R ⁵¹ , R ⁵² and R ⁵³ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Amidino group, or
(m) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasingyl, 3-, 6- or 7-cinnolinyl, 6- or 7-phthalanilyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-phthalininyl and 2-, 6- or 7-quinazolinyl is selected from the class consisting of aryl R ^43,
(Ii) methyl, which may be mono- or polysubstituted with a fluorine atom and mono-substituted with R ⁴³ ,
(Iii) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(Iii) a group of formula -COOR ⁵⁴ wherein R ⁵⁴ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(Iii) R ⁵⁵ and R ⁵⁶ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁵⁵ and R ⁵⁶ being between A group of the formula -NR ⁵⁵ R ⁵⁶ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of which one of R ⁵⁵ and R ⁵⁶ may also be a group R ⁴³ ,
(Iii) R ⁵⁷ and R ⁵⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁵⁷ and R ⁵⁸ together with a nitrogen atom in between A group of formula -CONR ⁵⁷ R ⁵⁸ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which forms a click ring, wherein one of R ⁵⁷ and R ⁵⁸ may also be a group R ⁴³ ,
(Iii) a group of formula -COR ⁵⁹ wherein R ⁵⁹ is a hydrogen atom, straight or branched chain alkyl of 1 to 5 carbon atoms, cycloalkyl of 3 to 5 carbon atoms or R ⁴³ ;
(Iii) a group of formula -OR ⁶⁰ wherein R ⁶⁰ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁴³ ;
(ix) a group of formula -SR ⁶¹ wherein R ⁶¹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁴³ ,
(x) cyano,
(xi) nitro, or
(xii) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasing, 3-, 6- or 7-cinnolinyl , 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7- puteri Aryl selected from the group consisting of diyl and 2-, 6- or 7-quinazolinyl,
R ⁴¹ is phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5 -Pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3- , 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- Or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6 Or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2-, 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3- , 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-quinolininyl, 3-, 6 Or 7-cinnolinyl, 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-phthyridinyl and 2-, 6- or 7-quinazolinyl Aryl selected from the group consisting of: wherein at least one hydrogen atom of said aryl group is
(A) one or more hydrogen atoms of the aryl group are each optionally
(Iii) branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(Ii) -COOH,
(Iii) -SO ₂ OH,
(Iii) -PO (OH) ₂ ,
(Iii) a group of formula -COOR ⁶³ wherein R ⁶³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(Iii) R ⁶⁴ and R ⁶⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁶⁴ and R ⁶⁵ being between A group of the formula -NR ⁶⁴ R ⁶⁵ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of
(Iii) R ⁶⁶ and R ⁶⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁶⁶ and R ⁶⁷ together with a nitrogen atom therebetween A group of the formula -CONR ⁶⁶ R ⁶⁷ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring,
(Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms;
(ix) a group of formula -SR ⁶⁹ wherein R ⁶⁹ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
(x) cyano,
(xi) nitro, or
(xii) R ⁷⁰ , R ⁷¹ and R ⁷² are each independently hydrogen atoms or alkyl or fluoroalkyl having 1 to 3 carbon atoms, and two of R ⁷⁰ , R ⁷¹ and R ⁷² are also nitrogen atom (s) in between; Formula with a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a heterocyclic ring together with Amidino group, or
(xiii) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasing, 3-, 6- or 7-cinnoli , 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7- puteri R ⁶² , which is aryl selected from the group consisting of diyl and 2-, 6- or 7-quinazolinyl;
(B) methyl, which may be mono- or polysubstituted with a fluorine atom and also monosubstituted with R ⁶² ,
(C) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(D) a group of formula -COOR ⁷³ wherein R ⁷³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(E) R ⁷⁴ and R ⁷⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or R ⁷⁴ and R ⁷⁵ between A group of formula -NR ⁷⁴ R ⁷⁵ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom of form a heterocyclic ring, one of R ⁷⁴ and R ⁷⁵ may also be a group R ⁶² ,
(F) R ⁷⁶ and R ⁷⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁷⁶ and R ⁷⁷ together with a nitrogen atom therebetween A group of formula -CONR ⁷⁶ R ⁷⁷ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms forming a click ring, wherein one of R ⁷⁶ and R ⁷⁷ can also be a group R ⁶² ,
(G) a group of formula -COR ⁷⁸ wherein R ⁷⁸ is a hydrogen atom, straight or branched chain alkyl of 1 to 5 carbon atoms, cycloalkyl of 3 to 5 carbon atoms or R ⁶² ,
(H) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
(I) a group of formula -SR ⁸⁰ wherein R ⁸⁰ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
(J) cyano,
(K) nitro, or
(L) can be replaced with halogen,
R ⁴ is Cl or trifluoromethyl,
R ⁵ and R ⁶ are each independently hydrogen, fluorine, chlorine, bromine or iodine atoms, methyl or trifluoromethyl.
[2" claim-type="Currently amended] A compound of formula (I) or a pharmaceutically acceptable salt thereof.
Formula I

In the above formula,
Y is oxygen or sulfur atom,
Z is oxygen or sulfur atom,
X is a divalent group of the formula> CHR ¹ ,> NR ¹ ,> CHSO ₂ R ¹ or> NSO ₂ R ¹ , or an oxygen or sulfur atom, wherein R ¹ is
(A) a hydrogen atom,
(B) an alkyl or cycloalkyl group is
(Iii) halogen,
(Ii) oxo,
(Iii) one or more hydrogen atoms of the aryl group are each optionally
(a) alkyl of 1 to 3 carbon atoms,
(b) -COOH,
(c) -SO ₂ OH,
(d) -PO (OH) ₂ ,
(e) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(f) R ⁸ and R ⁹ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or R ⁸ and R ⁹ are nitrogen atoms in between; A group of formula -NR ⁸ R ⁹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together form a heterocyclic ring;
(g) R ¹⁰ and R ¹¹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁰ and R ¹¹ together with the nitrogen atom therebetween form a heterocyclic ring A group of formula -CONR ¹⁰ R ¹¹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
(h) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(i) a group of formula -SR ^12b wherein R ^12b is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(j) cyano, or
(k) R ¹³ , R ¹⁴ and R ¹⁵ are each independently a hydrogen atom or alkyl of 1 to 3 carbon atoms, and two of R ¹³ , R ¹⁴ and R ¹⁵ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Phenyl, naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, which may be substituted by an amidino group of Isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, triazinyl, indolinyl, isoindoleyl, benzo [b] furanyl, benzo [b] thiophenyl, indazolyl, Consisting of benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, furinyl, quinolininyl, cinnolinyl, phthalanyl, quinoxalinyl, naphthyridinyl, pterridinyl and quinazolinyl Aryl selected from the class,
(Iii) a group of formula -COOR ¹⁶ wherein R ¹⁶ is straight or branched chain alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
(Iii) cyano,
(Iii) R ¹⁷ and R ¹⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁷ and R ¹⁸ together with the nitrogen atom therebetween form a heterocyclic ring; A group of formula -CONR ¹⁷ R ¹⁸ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
(Iii) a group of formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(Iii) a group of formula -SR ²⁰ wherein R ²⁰ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(Iii) R ²¹ and R ²² are each independently
(a) a hydrogen atom,
(b) alkyl or acyl or cycloalkyl of 3 to 7 carbon atoms,
(c) a group of the formula-(CH ₂ ) _m COOH, wherein m is 0, 1 or 2, or
(d) a group of the formula-(CH ₂ ) _n COOR ²³ , wherein n is 0, 1 or 2 and R ²³ is straight or branched chain alkyl of 1 to 6 carbon atoms, or R ²¹ and R ²² are between A group of formula -NR ²¹ R ²² constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of
(Iii) chemical formula Wherein R ²⁴ , R ²⁵ and R ²⁶ are each independently a branched or straight chain alkyl group having 1 to 7 carbon atoms and Q ⁻ is a chlorine, bromine or iodine counterion. Branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
(C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
(D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
(E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
(F) chemical formula (Where r is 2, 3, 4, 5 or 6, R ²⁷ , R ²⁸ and R ²⁹ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, and 2 of R ²⁷ , R ²⁸ and R ²⁹ ) May also constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom (s) therebetween form a heterocyclic ring,
(G) chemical formula (Wherein s is 2, 3, 4, 5 or 6, R ³⁰ , R ³¹ , R ³² and R ³³ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, R ³⁰ , R ³¹ , R ³² And two of R ³³ may also constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom (s) therebetween form a heterocyclic ring;
The nitrogen atom of the (H) group optionally
(Iii) alkyl having 1 to 3 carbon atoms,
(Ii) carboxylic ester groups having 2 to 7 carbon atoms,
(Iii) a carboxylic acid group having 2 to 5 carbon atoms,
(Iii) a phosphoric acid group having 1 to 6 carbon atoms, or
(Iii) piperidyl substituted with sulfuric acid groups of 1 to 6 carbon atoms, or
(I) one or more hydrogen atoms of the aryl group are each optionally
(Iii) alkyl having 1 to 3 carbon atoms,
(Ii) -COOH,
(Iii) -SO ₂ OH,
(Iii) -PO (OH) ₂ ,
(Iii) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(Iii) R ⁸ and R ⁹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁸ and R ⁹ are nitrogen atoms in between; A group of formula -NR ⁸ R ⁹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together form a heterocyclic ring;
(Iii) R ¹⁰ and R ¹¹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁰ and R ¹¹ together with a nitrogen atom therebetween form a heterocyclic ring A group of formula -CONR ¹⁰ R ¹¹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
(Iii) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(Iii) a group of formula -SR ^12b wherein R ^12b is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(x) cyano, or
(xi) R ¹³ , R ¹⁴ and R ¹⁵ are each independently a hydrogen atom or alkyl of 1 to 3 carbon atoms, and two of R ¹³ , R ¹⁴ and R ¹⁵ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Phenyl, naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, which may be substituted by an amidino group of Isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, triazinyl, indolinyl, isoindoleyl, benzo [b] furanyl, benzo [b] thiophenyl, indazolyl, Consisting of benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, furinyl, quinolininyl, cinnolinyl, phthalanyl, quinoxalinyl, naphthyridinyl, pterridinyl and quinazolinyl Aryl selected from the class
R ² is (A) a hydrogen atom, or
(B) alkyl or cycloalkyl groups are optionally
(Iii) a group of formula -OR ³⁴ wherein R ³⁴ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
(Ii) side chains having 1 to 3 carbon atoms, each of which R ³⁵ and R ³⁶ may each independently be substituted with a group of formula —NR ³⁵ R ³⁶ wherein a hydrogen atom, alkyl having 1 to 2 carbon atoms or acyl having 1 to 2 carbon atoms; Straight chain alkyl or cycloalkyl having 3 to 5 carbon atoms,
R ³ is a group of the formula-(CR ³⁷ R ³⁸ ) _x (CR ³⁹ R ⁴⁰ ) _y R ⁴¹ , wherein
x and y are each independently 0 or 1,
R ³⁷ , R ³⁸ and R ³⁹ are each independently
(A) a hydrogen atom,
(B) a group of formula -OR ⁴² , wherein R ⁴² is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
(C) branched or straight chain alkyl of 1 to 3 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
R ⁴⁰ is (A) a hydrogen atom,
(B) a group of formula -OR ⁴² , wherein R ⁴² is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(C) branched or straight chain alkyl of 1 to 3 carbon atoms or cycloalkyl of 3 to 5 carbon atoms, or
(D) at least one hydrogen atom of the aryl group is each optionally
(Iii) one or more hydrogen atoms of the aryl group are each optionally
(a) branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(b) -COOH,
(c) -SO ₂ OH,
(d) -PO (OH) ₂ ,
(e) a group of formula -COOR ⁴⁴ wherein R ⁴⁴ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(f) R ⁴⁵ and R ⁴⁶ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁴⁵ and R ⁴⁶ being between A group of the formula -NR ⁴⁵ R ⁴⁶ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together with the nitrogen atom of form a heterocyclic ring;
(g) R ⁴⁷ and R ⁴⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁴⁷ and R ⁴⁸ together with a nitrogen atom therebetween A group of formula -CONR ⁴⁷ R ⁴⁸ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a click ring,
(h) a group of formula -OR ⁴⁹ wherein R ⁴⁹ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
(i) a group of formula -SR ⁵⁰ wherein R ⁵⁰ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
(j) cyano,
(k) nitro,
(l) R ⁵¹ , R ⁵² and R ⁵³ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, and two of R ⁵¹ , R ⁵² and R ⁵³ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Amidino group, or
(m) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasingyl, 3-, 6- or 7-cinnolinyl, 6- or 7-phthalanilyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-phthalininyl and 2-, 6- or 7-quinazolinyl is selected from the class consisting of aryl R ^43,
(Ii) methyl, which may be mono- or polysubstituted with a fluorine atom and mono-substituted with R ⁴³ ,
(Iii) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(Iii) a group of formula -COOR ⁵⁴ wherein R ⁵⁴ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(Iii) R ⁵⁵ and R ⁵⁶ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁵⁵ and R ⁵⁶ being between A group of the formula -NR ⁵⁵ R ⁵⁶ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of which one of R ⁵⁵ and R ⁵⁶ may also be a group R ⁴³ ,
(Iii) R ⁵⁷ and R ⁵⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁵⁷ and R ⁵⁸ together with a nitrogen atom in between A group of formula -CONR ⁵⁷ R ⁵⁸ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which forms a click ring, wherein one of R ⁵⁷ and R ⁵⁸ may also be a group R ⁴³ ,
(Iii) a group of formula -COR ⁵⁹ wherein R ⁵⁹ is a hydrogen atom, straight or branched chain alkyl of 1 to 5 carbon atoms, cycloalkyl of 3 to 5 carbon atoms or R ⁴³ ;
(Iii) a group of formula -OR ⁶⁰ wherein R ⁶⁰ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁴³ ;
(ix) a group of formula -SR ⁶¹ wherein R ⁶¹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁴³ ,
(x) cyano,
(xi) nitro, or
(xii) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasing, 3-, 6- or 7-cinnolinyl , 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7- puteri Aryl selected from the group consisting of diyl and 2-, 6- or 7-quinazolinyl,
R ⁴¹ is phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5 -Pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3- , 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- Or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6 Or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2-, 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3- , 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-quinolininyl, 3-, 6 Or 7-cinnolinyl, 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-phthyridinyl and 2-, 6- or 7-quinazolinyl Aryl selected from the class consisting of one or more hydrogen atoms of the aryl
(A) one or more hydrogen atoms of the aryl group are each optionally
(Iii) branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(Ii) -COOH,
(Iii) -SO ₂ OH,
(Iii) -PO (OH) ₂ ,
(Iii) a group of formula -COOR ⁶³ wherein R ⁶³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(Iii) R ⁶⁴ and R ⁶⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁶⁴ and R ⁶⁵ being between A group of the formula -NR ⁶⁴ R ⁶⁵ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of
(Iii) R ⁶⁶ and R ⁶⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁶⁶ and R ⁶⁷ together with a nitrogen atom therebetween A group of the formula -CONR ⁶⁶ R ⁶⁷ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring,
(Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms;
(ix) a group of formula -SR ⁶⁹ wherein R ⁶⁹ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
(x) cyano,
(xi) nitro,
(xii) R ⁷⁰ , R ⁷¹ and R ⁷² are each independently hydrogen atoms or alkyl or fluoroalkyl having 1 to 3 carbon atoms, and two of R ⁷⁰ , R ⁷¹ and R ⁷² are also nitrogen atom (s) in between; Formula with a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a heterocyclic ring together with Amidino group, or
(xiii) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasing, 3-, 6- or 7-cinnoli , 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7- puteri R ⁶² , which is aryl selected from the group consisting of diyl and 2-, 6- or 7-quinazolinyl;
(B) methyl, which may be mono- or polysubstituted with a fluorine atom and also monosubstituted with R ⁶² ,
(C) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(D) a group of formula -COOR ⁷³ wherein R ⁷³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(E) R ⁷⁴ and R ⁷⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or R ⁷⁴ and R ⁷⁵ between A group of formula -NR ⁷⁴ R ⁷⁵ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom of form a heterocyclic ring, one of R ⁷⁴ and R ⁷⁵ may also be a group R ⁶² ,
(F) R ⁷⁶ and R ⁷⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁷⁶ and R ⁷⁷ together with a nitrogen atom therebetween A group of formula -CONR ⁷⁶ R ⁷⁷ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms forming a click ring, wherein one of R ⁷⁶ and R ⁷⁷ can also be a group R ⁶² ,
(G) a group of formula -COR ⁷⁸ wherein R ⁷⁸ is a hydrogen atom, straight or branched chain alkyl of 1 to 5 carbon atoms, cycloalkyl of 3 to 5 carbon atoms or R ⁶² ,
(H) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
(I) a group of formula -SR ⁸⁰ wherein R ⁸⁰ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
(J) cyano,
(K) nitro, or
(L) replaced by halogen,
R ⁴ is Cl or trifluoromethyl,
R ⁵ and R ⁶ are each independently hydrogen, fluorine, chlorine, bromine or iodine atoms, methyl or trifluoromethyl.
[3" claim-type="Currently amended] The method of claim 2,
Y is oxygen or sulfur atom,
Z is oxygen or sulfur atom,
X is a divalent group of formula> CHR ¹ ,> NR ¹ ,> CHSO ₂ R ¹ or> NSO ₂ R ¹ , or an oxygen or sulfur atom, wherein R ¹ is
(A) a hydrogen atom,
(B) an alkyl or cycloalkyl group is
(Iii) halogen,
(Ii) oxo,
(Iii) one or more hydrogen atoms of the aryl group are each optionally
(a) alkyl of 1 to 3 carbon atoms,
(b) -COOH,
(c) -SO ₂ OH,
(d) -PO (OH) ₂ ,
(e) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(f) R ⁸ and R ⁹ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or R ⁸ and R ⁹ are nitrogen atoms in between; A group of formula -NR ⁸ R ⁹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together form a heterocyclic ring;
(g) R ¹⁰ and R ¹¹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁰ and R ¹¹ together with the nitrogen atom therebetween form a heterocyclic ring A group of formula -CONR ¹⁰ R ¹¹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
(h) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(i) a group of formula -SR ^12b wherein R ^12b is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(j) cyano, or
(k) R ¹³ , R ¹⁴ and R ¹⁵ are each independently a hydrogen atom or alkyl of 1 to 3 carbon atoms, and two of R ¹³ , R ¹⁴ and R ¹⁵ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Phenyl, naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, which may be substituted by an amidino group of Isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, triazinyl, indolinyl, isoindoleyl, benzo [b] furanyl, benzo [b] thiophenyl, indazolyl, Consisting of benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, furinyl, quinolininyl, cinnolinyl, phthalanyl, quinoxalinyl, naphthyridinyl, pterridinyl and quinazolinyl Aryl selected from the class,
(Iii) a group of formula -COOR ¹⁶ wherein R ¹⁶ is straight or branched chain alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
(Iii) cyano,
(Iii) R ¹⁷ and R ¹⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁷ and R ¹⁸ together with the nitrogen atom therebetween form a heterocyclic ring; A group of formula -CONR ¹⁷ R ¹⁸ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
(Iii) a group of formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(Iii) a group of formula -SR ²⁰ wherein R ²⁰ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(Iii) R ²¹ and R ²² are each independently
(a) a hydrogen atom,
(b) alkyl or acyl or cycloalkyl of 3 to 7 carbon atoms,
(c) a group of the formula-(CH ₂ ) _m COOH, wherein m is 0, 1 or 2, or
(d) a group of the formula-(CH ₂ ) _n COOR ²³ , wherein n is 0, 1 or 2 and R ²³ is straight or branched chain alkyl of 1 to 6 carbon atoms, or R ²¹ and R ²² are between A group of formula -NR ²¹ R ²² constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of
(Iii) chemical formula Where R ²⁴ , R ²⁵ and R ²⁶ are each independently a branched or straight chain alkyl group of 1 to 7 carbon atoms and Q ⁻ is a monosubstituted quaternary group of chlorine, bromine or iodine counterion, Branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
(C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
(D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
(E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
(F) chemical formula (Where r is 2, 3, 4, 5 or 6, R ²⁷ , R ²⁸ and R ²⁹ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, and 2 of R ²⁷ , R ²⁸ and R ²⁹ ) May also constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom (s) therebetween form a heterocyclic ring,
(G) chemical formula (Wherein s is 2, 3, 4, 5 or 6, R ³⁰ , R ³¹ , R ³² and R ³³ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, R ³⁰ , R ³¹ , R ³² And two of R ³³ may also constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom (s) therebetween form a heterocyclic ring), or a guanidino group of
The nitrogen atom of the (H) group optionally
(Iii) alkyl having 1 to 3 carbon atoms,
(Ii) carboxylic ester groups having 2 to 7 carbon atoms,
(Iii) a carboxylic acid group having 2 to 5 carbon atoms,
(Iii) a phosphoric acid group having 1 to 6 carbon atoms, or
(Iii) piperidyl substituted with a sulfuric acid group having 1 to 6 carbon atoms,
R ² is (A) a hydrogen atom, or
(B) methyl,
R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
R ⁴¹ is phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5 -Pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3- , 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- Or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6 Or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2-, 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3- , 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-quinolininyl, 3-, 6 Or 7-cinnolinyl, 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-phthyridinyl and 2-, 6- or 7-quinazolinyl Aryl selected from the group consisting of: wherein at least one hydrogen atom of said aryl is independently
(A) one or more hydrogen atoms of the aryl group are each optionally
(Iii) branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(Ii) -COOH,
(Iii) -SO ₂ OH,
(Iii) -PO (OH) ₂ ,
(Iii) a group of formula -COOR ⁶³ wherein R ⁶³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(Iii) R ⁶⁴ and R ⁶⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁶⁴ and R ⁶⁵ being between A group of the formula -NR ⁶⁴ R ⁶⁵ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of
(Iii) R ⁶⁶ and R ⁶⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁶⁶ and R ⁶⁷ together with a nitrogen atom therebetween A group of the formula -CONR ⁶⁶ R ⁶⁷ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring,
(Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms;
(ix) a group of formula -SR ⁶⁹ wherein R ⁶⁹ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
(x) cyano,
(xi) nitro,
(xii) R ⁷⁰ , R ⁷¹ and R ⁷² are each independently hydrogen atoms or alkyl or fluoroalkyl having 1 to 3 carbon atoms, and two of R ⁷⁰ , R ⁷¹ and R ⁷² are also nitrogen atom (s) in between; Formula with a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a heterocyclic ring together with Amidino group, or
(xiii) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasing, 3-, 6- or 7-cinnoli , 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7- puteri R ⁶² , which is aryl selected from the group consisting of diyl and 2-, 6- or 7-quinazolinyl;
(B) methyl, which may be mono- or polysubstituted with a fluorine atom and also monosubstituted with R ⁶² ,
(C) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(D) a group of formula -COOR ⁷³ wherein R ⁷³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(E) R ⁷⁴ and R ⁷⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or R ⁷⁴ and R ⁷⁵ between A group of formula -NR ⁷⁴ R ⁷⁵ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom of form a heterocyclic ring, one of R ⁷⁴ and R ⁷⁵ may also be a group R ⁶² ,
(F) R ⁷⁶ and R ⁷⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁷⁶ and R ⁷⁷ together with a nitrogen atom therebetween A group of formula -CONR ⁷⁶ R ⁷⁷ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms forming a click ring, wherein one of R ⁷⁶ and R ⁷⁷ can also be a group R ⁶² ,
(G) a group of formula -COR ⁷⁸ wherein R ⁷⁸ is a hydrogen atom, straight or branched chain alkyl of 1 to 5 carbon atoms, cycloalkyl of 3 to 5 carbon atoms or R ⁶² ,
(H) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
(I) a group of formula -SR ⁸⁰ wherein R ⁸⁰ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
(J) cyano,
(K) nitro, or
(L) replaced by halogen,
R ⁴ is Cl or trifluoromethyl,
A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R ⁵ and R ⁶ are each independently hydrogen, fluorine, chlorine, bromine or iodine atoms, methyl or trifluoromethyl.
[4" claim-type="Currently amended] The method of claim 3,
Y is an oxygen atom,
Z is an oxygen atom,
X is a divalent group of formula> CHR ¹ or> NR ¹ , wherein R ¹ is
(A) a hydrogen atom,
(B) an alkyl or cycloalkyl group is
(Iii) oxo,
(Ii) one or more hydrogen atoms of the aryl group are each optionally
(a) alkyl of 1 to 3 carbon atoms,
(b) -COOH,
(c) -SO ₂ OH,
(d) -PO (OH) ₂ ,
(e) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(f) a group of the formula -NH ₂ ,
(g) a group of the formula -CONH ₂ ,
(h) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or methyl,
(i) R ¹³ , R ¹⁴ and R ¹⁵ are each a hydrogen atom Phenyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, isothiazolyl, oxadia, which may be replaced by an amidino group of Aryl selected from the group consisting of zolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl and triazinyl,
(Iii) a group of formula -COOR ¹⁶ wherein R ¹⁶ is straight or branched chain alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
(Iii) a group of formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
(Iii) chemical formula Branched or straight-chain alkyl or carbon atoms having 1 to 6 carbon atoms, which may be monosubstituted into quaternary groups, wherein R ²⁴ , R ²⁵ and R ²⁶ are each methyl and Q ⁻ is a chlorine, bromine or iodine counterion; 3 to 6 cycloalkyl,
(C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
(D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
(E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
(F) chemical formula An amidino group, wherein r is 2, 3, 4, 5 or 6, and R ²⁷ , R ²⁸ and R ²⁹ are each hydrogen atoms,
(G) chemical formula Guanidino groups, wherein s is 2, 3, 4, 5 or 6, and R ³⁰ , R ³¹ , R ³² and R ³³ are each hydrogen atoms, or
The nitrogen atom of the (H) group optionally
(Iii) alkyl having 1 to 3 carbon atoms,
(Ii) carboxylic ester groups having 2 to 7 carbon atoms,
(Iii) a carboxylic acid group having 2 to 5 carbon atoms,
(Iii) a phosphoric acid group having 1 to 6 carbon atoms, or
(Iii) piperidyl substituted with a sulfuric acid group having 1 to 6 carbon atoms,
R ² is (A) a hydrogen atom, or
(B) methyl,
R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
R ⁴¹ is phenyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, isothiazolyl, oxadizolyl, triazolyl, thiadia Aryl selected from the group consisting of zolyl, pyridazinyl, pyrazinyl and triazinyl, wherein at least one hydrogen atom of the aryl group is necessarily independently
(A) one or more hydrogen atoms of the aryl group are each optionally
(Iii) methyl,
(Ii) -COOH,
(Iii) -SO ₂ OH,
(Iii) -PO (OH) ₂ ,
(Iii) a group of formula -COOR ^{63 wherein} R ⁶³ is methyl,
(Iii) a group of formula -NR ⁶⁴ R ⁶⁵ in which R ⁶⁴ and R ⁶⁵ are each independently hydrogen or methyl;
(Iii) a group of formula -CONR ⁶⁶ R ⁶⁷ wherein R ⁶⁶ and R ⁶⁷ are each independently hydrogen or methyl;
(Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or methyl;
(ix) a group of formula -SR ⁶⁹ wherein R ⁶⁹ is a hydrogen atom or methyl,
(x) cyano,
(xi) nitro, or
(xii) phenyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, isothiazolyl, oxadia, which may be replaced by halogen R ⁶² , which is an aryl selected from the group consisting of zolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl and triazinyl;
(B) methyl, which may be mono- or polysubstituted with a fluorine atom and also monosubstituted with R ⁶² ,
(C) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(D) a group of formula -COOR ^{73 wherein} R ⁷³ is methyl,
(E) a group of formula -NR ⁷⁴ R ⁷⁵ , wherein R ⁷⁴ and R ⁷⁵ are each independently a hydrogen atom or methyl, and one of R ⁷⁴ and R ⁷⁵ can also be a group R ⁶² ,
(F) a group of formula -CONR ⁷⁶ R ⁷⁷ , wherein R ⁷⁶ and R ⁷⁷ are each independently a hydrogen atom or methyl, and one of R ⁷⁶ and R ⁷⁷ can also be a group R ⁶² ,
(G) a group of formula -COR ^{78 wherein} R ⁷⁸ is a hydrogen atom, methyl or R ⁶² ,
(H) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, methyl or R ⁶² ,
(I) a group of formula -SR ⁸⁰ , wherein R ⁸⁰ is a hydrogen atom, methyl or R ⁶² ,
(J) cyano,
(K) nitro, or
(L) replaced by halogen,
R ⁴ is Cl or trifluoromethyl,
R ⁵ is a hydrogen atom,
A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R ⁶ is Cl or trifluoromethyl.
[5" claim-type="Currently amended] The method of claim 4, wherein
Y is an oxygen atom,
Z is an oxygen atom,
X is a divalent group of formula> CHR ¹ or> NR ¹ , wherein R ¹ is
(A) a hydrogen atom,
(B) an alkyl or cycloalkyl group is
(Iii) oxo,
(Ii) one or more hydrogen atoms of the aryl group are each optionally
(a) alkyl of 1 to 3 carbon atoms,
(b) -COOH,
(c) -SO ₂ OH,
(d) -PO (OH) ₂ ,
(e) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(f) a group of the formula -NH ₂ ,
(g) a group of the formula -CONH ₂ ,
(h) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or methyl,
(i) R ¹³ , R ¹⁴ and R ¹⁵ are each a hydrogen atom Phenyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, isothiazolyl, oxadia, which may be replaced by an amidino group of Aryl selected from the group consisting of zolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl and triazinyl,
(Iii) a group of formula -COOR ¹⁶ wherein R ¹⁶ is straight or branched chain alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
(Iii) a group of formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
(Iii) chemical formula Branched or straight-chain alkyl or carbon atoms having 1 to 6 carbon atoms, which may be monosubstituted into quaternary groups, wherein R ²⁴ , R ²⁵ and R ²⁶ are each methyl and Q ⁻ is a chlorine, bromine or iodine counterion; 3 to 6 cycloalkyl,
(C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
(D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
(E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
(F) chemical formula An amidino group, wherein r is 2, 3, 4, 5 or 6, and R ²⁷ , R ²⁸ and R ²⁹ are each hydrogen atoms,
(G) chemical formula Guanidino groups, wherein s is 2, 3, 4, 5 or 6, and R ³⁰ , R ³¹ , R ³² and R ³³ are each hydrogen atoms, or
The nitrogen atom of the (H) group optionally
(Iii) alkyl having 1 to 3 carbon atoms,
(Ii) carboxylic ester groups having 2 to 7 carbon atoms,
(Iii) a carboxylic acid group having 2 to 5 carbon atoms,
(Iii) a phosphoric acid group having 1 to 6 carbon atoms, or
(Iii) piperidyl substituted with a sulfuric acid group having 1 to 6 carbon atoms,
R ² is (A) a hydrogen atom, or
(B) methyl,
R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
R ⁴¹ is selected from the group consisting of phenyl, thiophenyl, pyridyl, pyrimidinyl, furyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl and pyrazinyl Aryl, wherein at least one hydrogen atom of the aryl group is necessarily
(A) one or more hydrogen atoms of the aryl group are each optionally
(Iii) methyl,
(Ii) -COOH,
(Iii) a group of formula -COOR ^{63 wherein} R ⁶³ is methyl,
(Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or methyl; or
(Iii) phenyl, thiophenyl, pyridyl, pyrimidinyl, furyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, which may be replaced by halogen, and R ⁶² , which is aryl selected from the group consisting of pyrazinyl,
(B) a fluorine atom-yl-methyl, or is optionally substituted or may be substituted by R ^62,
(C) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(D) a group of formula -COOR ^{73 wherein} R ⁷³ is methyl,
(E) a group of formula -CONR ⁷⁶ R ⁷⁷ wherein R ⁷⁶ and R ⁷⁷ are each methyl, one of R ⁷⁶ and R ⁷⁷ is methyl and the other is group R ⁶² ,
(F) a group of formula -COR ^{78 wherein} R ⁷⁸ is a hydrogen atom, methyl or R ⁶² ,
(G) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, methyl or R ⁶² ,
(H) cyano,
(I) nitro, or
(J) replaced with halogen,
R ⁴ is Cl or trifluoromethyl,
R ⁵ is a hydrogen atom,
A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R ⁶ is Cl or trifluoromethyl.
[6" claim-type="Currently amended] The method of claim 5,
Y is an oxygen atom,
Z is an oxygen atom,
X is a divalent group of formula> CHR ¹ or> NR ¹ , wherein R ¹ is
(A) a hydrogen atom,
(B) an alkyl or cycloalkyl group is
(Iii) oxo,
(Ii) one or more hydrogen atoms of the aryl group are each optionally
(a) alkyl of 1 to 3 carbon atoms,
(b) -COOH,
(c) -SO ₂ OH,
(d) -PO (OH) ₂ ,
(e) a group of formula -OR ^12a , wherein R ^12a is a hydrogen atom or methyl,
(f) Formulas R ¹³ , R ¹⁴ and R ¹⁵ are each hydrogen atoms Aryl selected from the group consisting of phenyl or pyridyl, which may be replaced by an amidino group of
(Iii) a group of formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
(Iii) chemical formula Branched or straight-chain alkyl or carbon atoms having 1 to 6 carbon atoms, which may be monosubstituted into quaternary groups, wherein R ²⁴ , R ²⁵ and R ²⁶ are each methyl and Q ⁻ is a chlorine, bromine or iodine counterion; 3 to 6 cycloalkyl,
(C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
(D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
(E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
(F) chemical formula An amidino group, wherein r is 2, 3, 4, 5 or 6, and R ²⁷ , R ²⁸ and R ²⁹ are each hydrogen atoms,
(G) chemical formula Guanidino groups, wherein s is 2, 3, 4, 5 or 6, and R ³⁰ , R ³¹ , R ³² and R ³³ are each hydrogen atoms, or
The nitrogen atom of the (H) group optionally
(Iii) alkyl having 1 to 3 carbon atoms,
(Ii) carboxylic ester groups having 2 to 7 carbon atoms,
(Iii) a carboxylic acid group having 2 to 5 carbon atoms,
(Iii) a phosphoric acid group having 1 to 6 carbon atoms, or
(Iii) piperidyl substituted with a sulfuric acid group having 1 to 6 carbon atoms,
R ² is (A) a hydrogen atom, or
(B) methyl,
R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
R ⁴¹ is aryl selected from the group consisting of phenyl or pyridyl, wherein at least one hydrogen atom of the aryl group is necessarily
(A) one or more hydrogen atoms of the aryl group are each optionally
(Iii) methyl,
(Ii) -COOH,
(Iii) a group of formula -COOR ^{63 wherein} R ⁶³ is methyl,
(Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or methyl; or
(Iii) R ⁶² , which is aryl selected from the class consisting of phenyl or pyridyl, which may be replaced by halogen;
(B) a fluorine atom-yl-methyl, or is optionally substituted or may be substituted by R ^62,
(C) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted with fluorine or oxo,
(D) a group of formula -COOR ^{73 wherein} R ⁷³ is methyl,
(E) a group of formula -CONR ⁷⁶ R ⁷⁷ wherein R ⁷⁶ and R ⁷⁷ are each methyl, one of R ⁷⁶ and R ⁷⁷ is methyl and the other is group R ⁶² ,
(F) a group of formula -COR ^{78 wherein} R ⁷⁸ is a hydrogen atom, methyl or R ⁶² ,
(G) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, methyl or R ⁶² ,
(H) cyano,
(I) nitro, or
(J) replaced with halogen,
R ⁴ is chlorine or trifluoromethyl,
R ⁵ is a hydrogen atom,
A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R ⁶ is a chlorine atom or trifluoromethyl.
[7" claim-type="Currently amended] The method of claim 6,
Y is an oxygen atom,
Z is an oxygen atom,
X is a divalent group of formula> CHR ¹ or> NR ¹ , wherein R ¹ is
(A) a hydrogen atom,
(B) (vi) oxo,
(Ii) at least one hydrogen atom of the aryl group is optionally
(a) alkyl of 1 to 3 carbon atoms,
(b) -COOH,
(c) -SO ₂ OH,
(d) -PO (OH) ₂ ,
(e) a group of formula -OR ^12a , wherein R ^12a is a hydrogen atom or methyl, or
(f) Formulas R ¹³ , R ¹⁴ and R ¹⁵ are each hydrogen atoms Aryl selected from the class consisting of phenyl or pyridyl, which may be replaced by an amidino group of
(Iii) alkyl having 1 to 2 carbon atoms which may be monosubstituted with a group of the formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or methyl,
(C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
(D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
(E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
(F) chemical formula An amidino group, wherein r is 2, 3, 4, 5 or 6, and R ²⁷ , R ²⁸ and R ²⁹ are each hydrogen atoms, or
(G) chemical formula (Where s is 2, 3, 4, 5 or 6, and R ³⁰ , R ³¹ , R ³² and R ³³ are each hydrogen atoms), and are guanidino groups of
R ² is (A) a hydrogen atom, or
(B) methyl,
R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
R ⁴¹ is phenyl, wherein at least one hydrogen atom of the phenyl group is necessarily
(A) one or more hydrogen atoms of the aryl group are each optionally
(Iii) methyl,
(Ii) a group of formula -COOR ^{63 wherein} R ⁶³ is methyl,
(Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or methyl; or
(Iii) R ⁶² , which is aryl selected from the class consisting of phenyl or pyridyl, which may be replaced by halogen;
(B) a fluorine atom-yl-methyl, or is optionally substituted or may be substituted by R ^62,
(C) a group of formula -COOR ^{73 wherein} R ⁷³ is methyl,
(D) a group of formula -COR ^{78 wherein} R ⁷⁸ is methyl or R ⁶² ,
(E) a group of the formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, methyl or R ⁶² ,
(F) cyano,
(G) nitro, or
(H) replaced by halogen,
R ⁴ is a chlorine atom or trifluoromethyl,
R ⁵ is a hydrogen atom,
A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R ⁶ is a chlorine atom or trifluoromethyl.
[8" claim-type="Currently amended] The method of claim 7, wherein
Y is an oxygen atom,
Z is an oxygen atom,
X is a divalent group of formula> NR ¹ , wherein R ¹ is
(A) a hydrogen atom,
(B) methyl or ethyl, or
(C) -COCH ₃ ,
R ² is (A) a hydrogen atom, or
(B) methyl,
R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
R ⁴¹ is phenyl, wherein at least one hydrogen atom of the phenyl group is necessarily
(A) one or more hydrogen atoms of the aryl group are each optionally
(Iii) methyl,
(Ii) a group of formula -COOR ^{63 wherein} R ⁶³ is methyl,
(Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or methyl; or
(Iii) R ⁶² , which is aryl selected from the class consisting of phenyl or pyridyl, which may be replaced by halogen;
(B) a fluorine atom-yl-methyl, or is optionally substituted or may be substituted by R ^62,
(C) a group of formula -COOR ^{73 wherein} R ⁷³ is methyl,
(D) a group of formula -COR ^{78 wherein} R ⁷⁸ is methyl or R ⁶² ,
(E) a group of the formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, methyl or R ⁶² ,
(F) cyano,
(G) nitro, or
(H) replaced by halogen,
R ⁴ is a chlorine atom or trifluoromethyl,
R ⁵ is a hydrogen atom,
A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R ⁶ is a chlorine atom or trifluoromethyl.
[9" claim-type="Currently amended] The method of claim 8,
Y is an oxygen atom,
Z is an oxygen atom,
X is a divalent group of formula> NR ¹ , wherein R ¹ is
(A) a hydrogen atom,
(B) methyl or ethyl, or
(C) -COCH ₃ ,
R ² is (A) a hydrogen atom, or
(B) methyl,
R ³ is a group of the formula -CH ₂ R ⁴¹ , wherein
R ⁴¹ is phenyl, wherein at least one hydrogen atom of the phenyl group is necessarily
(A) one or more hydrogen atoms of the aryl group are each optionally
(Iii) methyl, or
(Ii) R ^{62 which is} aryl selected from the class consisting of phenyl or pyridyl, which may be replaced by halogen;
(B) methyl, which may be mono- or polysubstituted with fluorine atoms,
(C) a group of formula -COR ^{78 wherein} R ⁷⁸ is methyl or R ⁶² ,
(D) replaced with halogen,
R ⁴ is a chlorine atom,
R ⁵ is a hydrogen atom,
A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R ⁶ is a chlorine atom.
[10" claim-type="Currently amended]
A compound selected from the group consisting of or a pharmaceutically acceptable salt thereof.
[11" claim-type="Currently amended] Comprising administering a compound according to claim 2, 3, 4, 5, 6, 7, 8, 9, or 10 in a prophylactic or therapeutic amount, A method for treating or preventing an inflammatory immune cell-mediated disease or condition.
[12" claim-type="Currently amended] 12. The tissue according to claim 1 or 11, wherein the disease or condition is adult respiratory distress syndrome, shock, oxygen toxicity, secondary multiple organ injury syndrome to sepsis, secondary multiple organ injury syndrome to trauma, tissue due to cardiopulmonary bypass Perfusion disease, myocardial infarction or use of thrombolytic agents, acute glomerulonephritis, vasculitis, reactive arthritis, skin diseases with acute inflammatory factors, seizures, burns, hemodialysis, leukopenia, ulcerative colitis, necrotizing colitis and Granule cell transfusion related syndrome.
[13" claim-type="Currently amended] The disease or condition according to claim 1 or 11, wherein the disease or condition is psoriasis, organ / tissue transplant rejection, graft-versus-host response and autoimmune diseases, including Raynaud's syndrome, autoimmune thyroiditis, dermatitis, multiple sclerosis, rheumatoid arthritis Inflammatory bowel disease and ulcerative colitis, including insulin-dependent diabetes, uveitis, Crohn's disease; And systemic lupus erythema.
[14" claim-type="Currently amended] The method of claim 1 or 11, wherein the disease or condition is asthma.
[15" claim-type="Currently amended] The method of claim 1 or 11, wherein the condition is toxic associated with cytokine treatment.
[16" claim-type="Currently amended] A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I).
Formula I

In the above formula,
Y is oxygen or sulfur atom,
Z is oxygen or sulfur atom,
X is a divalent group of the formula> CHR ¹ ,> NR ¹ ,> CHSO ₂ R ¹ or> NSO ₂ R ¹ , or an oxygen or sulfur atom, wherein R ¹ is
(A) a hydrogen atom,
(B) an alkyl or cycloalkyl group is
(Iii) halogen,
(Ii) oxo,
(Iii) one or more hydrogen atoms of the aryl group are each optionally
(a) alkyl of 1 to 3 carbon atoms,
(b) -COOH,
(c) -SO ₂ OH,
(d) -PO (OH) ₂ ,
(e) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(f) R ⁸ and R ⁹ are each independently a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or R ⁸ and R ⁹ are nitrogen atoms in between; A group of formula -NR ⁸ R ⁹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together form a heterocyclic ring;
(g) R ¹⁰ and R ¹¹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁰ and R ¹¹ together with the nitrogen atom therebetween form a heterocyclic ring A group of formula -CONR ¹⁰ R ¹¹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
(h) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(i) a group of formula -SR ^12b wherein R ^12b is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(j) cyano, or
(k) R ¹³ , R ¹⁴ and R ¹⁵ are each independently a hydrogen atom or alkyl of 1 to 3 carbon atoms, and two of R ¹³ , R ¹⁴ and R ¹⁵ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Phenyl, naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, which may be substituted by an amidino group of Isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, triazinyl, indolinyl, isoindoleyl, benzo [b] furanyl, benzo [b] thiophenyl, indazolyl, Consisting of benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, furinyl, quinolininyl, cinnolinyl, phthalanyl, quinoxalinyl, naphthyridinyl, pterridinyl and quinazolinyl Aryl selected from the class,
(Iii) a group of formula -COOR ¹⁶ wherein R ¹⁶ is straight or branched chain alkyl of 1 to 7 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
(Iii) cyano,
(Iii) R ¹⁷ and R ¹⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁷ and R ¹⁸ together with the nitrogen atom therebetween form a heterocyclic ring; A group of formula -CONR ¹⁷ R ¹⁸ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
(Iii) a group of formula -OR ¹⁹ wherein R ¹⁹ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(Iii) a group of formula -SR ²⁰ wherein R ²⁰ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(Iii) R ²¹ and R ²² are each independently
(a) a hydrogen atom,
(b) alkyl or acyl or cycloalkyl of 3 to 7 carbon atoms,
(c) a group of the formula-(CH ₂ ) _m COOH, wherein m is 0, 1 or 2, or
(d) a group of the formula-(CH ₂ ) _n COOR ²³ , wherein n is 0, 1 or 2 and R ²³ is straight or branched chain alkyl of 1 to 6 carbon atoms, or R ²¹ and R ²² are between A group of formula -NR ²¹ R ²² constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of
(Iii) chemical formula Wherein R ²⁴ , R ²⁵ and R ²⁶ are each independently a branched or straight chain alkyl group having 1 to 7 carbon atoms and Q ⁻ is a chlorine, bromine or iodine counterion. Branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms,
(C) branched or straight chain carboxylic acid group having 3 to 6 carbon atoms,
(D) branched or straight chain phosphoric acid groups having 2 to 6 carbon atoms,
(E) branched or straight chain sulfuric acid groups having 2 to 6 carbon atoms,
(F) chemical formula (Where r is 2, 3, 4, 5 or 6, R ²⁷ , R ²⁸ and R ²⁹ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, and 2 of R ²⁷ , R ²⁸ and R ²⁹ ) May also constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom (s) therebetween form a heterocyclic ring,
(G) chemical formula (Wherein s is 2, 3, 4, 5 or 6, R ³⁰ , R ³¹ , R ³² and R ³³ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, R ³⁰ , R ³¹ , R ³² And two of R ³³ may also constitute a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom (s) therebetween form a heterocyclic ring;
The nitrogen atom of the (H) group optionally
(Iii) alkyl having 1 to 3 carbon atoms,
(Ii) carboxylic ester groups having 2 to 7 carbon atoms,
(Iii) a carboxylic acid group having 2 to 5 carbon atoms,
(Iii) a phosphoric acid group having 1 to 6 carbon atoms, or
(Iii) piperidyl substituted with sulfuric acid groups of 1 to 6 carbon atoms, or
(I) one or more hydrogen atoms of the aryl group are each optionally
(Iii) alkyl having 1 to 3 carbon atoms,
(Ii) -COOH,
(Iii) -SO ₂ OH,
(Iii) -PO (OH) ₂ ,
(Iii) a group of formula -COOR ⁷ wherein R ⁷ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(Iii) R ⁸ and R ⁹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁸ and R ⁹ are nitrogen atoms in between; A group of formula -NR ⁸ R ⁹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together form a heterocyclic ring;
(Iii) R ¹⁰ and R ¹¹ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, or R ¹⁰ and R ¹¹ together with a nitrogen atom therebetween form a heterocyclic ring A group of formula -CONR ¹⁰ R ¹¹ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms,
(Iii) a group of formula -OR ^12a wherein R ^12a is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(Iii) a group of formula -SR ^12b wherein R ^12b is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(x) cyano, or
(xi) R ¹³ , R ¹⁴ and R ¹⁵ are each independently a hydrogen atom or alkyl of 1 to 3 carbon atoms, and two of R ¹³ , R ¹⁴ and R ¹⁵ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Phenyl, naphthyl, indolyl, thiophenyl, pyridyl, pyrimidinyl, furyl, pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, which may be substituted by an amidino group of Isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, triazinyl, indolinyl, isoindoleyl, benzo [b] furanyl, benzo [b] thiophenyl, indazolyl, Consisting of benzthiazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, furinyl, quinolininyl, cinnolinyl, phthalanyl, quinoxalinyl, naphthyridinyl, pterridinyl and quinazolinyl Aryl selected from the class
R ² is (A) a hydrogen atom, or
(B) alkyl or cycloalkyl groups are optionally
(Iii) a group of formula -OR ³⁴ wherein R ³⁴ is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
(Ii) side chains having 1 to 3 carbon atoms, each of which R ³⁵ and R ³⁶ may each independently be substituted with a group of formula —NR ³⁵ R ³⁶ wherein a hydrogen atom, alkyl having 1 to 2 carbon atoms or acyl having 1 to 2 carbon atoms; Straight chain alkyl or cycloalkyl having 3 to 5 carbon atoms,
R ³ is a group of the formula-(CR ³⁷ R ³⁸ ) _x (CR ³⁹ R ⁴⁰ ) _y R ⁴¹ , wherein
x and y are each independently 0 or 1,
R ³⁷ , R ³⁸ and R ³⁹ are each independently
(A) a hydrogen atom,
(B) a group of formula -OR ⁴² , wherein R ⁴² is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms, or
(C) branched or straight chain alkyl of 1 to 3 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
R ⁴⁰ is (A) a hydrogen atom,
(B) a group of formula -OR ⁴² , wherein R ⁴² is a hydrogen atom or an alkyl or acyl group having 1 to 7 carbon atoms,
(C) branched or straight chain alkyl of 1 to 3 carbon atoms or cycloalkyl of 3 to 5 carbon atoms, or
(D) at least one hydrogen atom of the aryl group is each optionally
(Iii) one or more hydrogen atoms of the aryl group are each optionally
(a) branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(b) -COOH,
(c) -SO ₂ OH,
(d) -PO (OH) ₂ ,
(e) a group of formula -COOR ⁴⁴ wherein R ⁴⁴ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(f) R ⁴⁵ and R ⁴⁶ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁴⁵ and R ⁴⁶ being between A group of the formula -NR ⁴⁵ R ⁴⁶ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which together with the nitrogen atom of form a heterocyclic ring;
(g) R ⁴⁷ and R ⁴⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁴⁷ and R ⁴⁸ together with a nitrogen atom therebetween A group of formula -CONR ⁴⁷ R ⁴⁸ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a click ring,
(h) a group of formula -OR ⁴⁹ wherein R ⁴⁹ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
(i) a group of formula -SR ⁵⁰ wherein R ⁵⁰ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
(j) cyano,
(k) nitro,
(l) R ⁵¹ , R ⁵² and R ⁵³ are each independently a hydrogen atom or alkyl having 1 to 3 carbon atoms, and two of R ⁵¹ , R ⁵² and R ⁵³ are also heterocyclic with the nitrogen atom (s) in between; Chemical formula capable of constructing a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring Amidino group, or
(m) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasingyl, 3-, 6- or 7-cinnolinyl, 6- or 7-phthalanilyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-phthalininyl and 2-, 6- or 7-quinazolinyl is selected from the class consisting of aryl R ^43,
(Ii) methyl, which may be mono- or polysubstituted with a fluorine atom and mono-substituted with R ⁴³ ,
(Iii) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(Iii) a group of formula -COOR ⁵⁴ wherein R ⁵⁴ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(Iii) R ⁵⁵ and R ⁵⁶ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁵⁵ and R ⁵⁶ being between A group of the formula -NR ⁵⁵ R ⁵⁶ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of which one of R ⁵⁵ and R ⁵⁶ may also be a group R ⁴³ ,
(Iii) R ⁵⁷ and R ⁵⁸ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁵⁷ and R ⁵⁸ together with a nitrogen atom in between A group of formula -CONR ⁵⁷ R ⁵⁸ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which forms a click ring, wherein one of R ⁵⁷ and R ⁵⁸ may also be a group R ⁴³ ,
(Iii) a group of formula -COR ⁵⁹ wherein R ⁵⁹ is a hydrogen atom, straight or branched chain alkyl of 1 to 5 carbon atoms, cycloalkyl of 3 to 5 carbon atoms or R ⁴³ ;
(Iii) a group of formula -OR ⁶⁰ wherein R ⁶⁰ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁴³ ;
(ix) a group of formula -SR ⁶¹ wherein R ⁶¹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁴³ ,
(x) cyano,
(xi) nitro, or
(xii) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasing, 3-, 6- or 7-cinnolinyl , 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7- puteri Aryl selected from the group consisting of diyl and 2-, 6- or 7-quinazolinyl,
R ⁴¹ is phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5 -Pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1-, 3- , 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-isothiazolyl, 4- Or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6 Or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2-, 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimidazolyl, 2-, 3- , 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-quinolininyl, 3-, 6 Or 7-cinnolinyl, 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7-phthyridinyl and 2-, 6- or 7-quinazolinyl Aryl selected from the group consisting of: wherein at least one hydrogen atom of said aryl group is
(A) one or more hydrogen atoms of the aryl group are each optionally
(Iii) branched or straight chain alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(Ii) -COOH,
(Iii) -SO ₂ OH,
(Iii) -PO (OH) ₂ ,
(Iii) a group of formula -COOR ⁶³ wherein R ⁶³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(Iii) R ⁶⁴ and R ⁶⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 6 carbon atoms or acyl having 1 to 7 carbon atoms, or R ⁶⁴ and R ⁶⁵ being between A group of the formula -NR ⁶⁴ R ⁶⁵ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms which forms a heterocyclic ring with a nitrogen atom of
(Iii) R ⁶⁶ and R ⁶⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁶⁶ and R ⁶⁷ together with a nitrogen atom therebetween A group of the formula -CONR ⁶⁶ R ⁶⁷ constituting a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a click ring,
(Iii) a group of formula -OR ⁶⁸ wherein R ⁶⁸ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms;
(ix) a group of formula -SR ⁶⁹ wherein R ⁶⁹ is a hydrogen atom or an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms,
(x) cyano,
(xi) nitro, or
(xii) R ⁷⁰ , R ⁷¹ and R ⁷² are each independently hydrogen atoms or alkyl or fluoroalkyl having 1 to 3 carbon atoms, and two of R ⁷⁰ , R ⁷¹ and R ⁷² are also nitrogen atom (s) in between; Formula with a saturated hydrocarbon bridge having 3 to 5 carbon atoms to form a heterocyclic ring together with Amidino group, or
(xiii) phenyl, 2-naphthyl, 2-, 3-, 5- or 6-indolyl, 2- or 3-thiophenyl, 2-, 3- or 4-pyridyl, which may be replaced by halogen, 2-, 4- or 5-pyrimidinyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thia Zolyl, 1-, 3-, 4- or 5-pyrazolyl, 3-, 4- or 5-isoxazolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5 Isothiazolyl, 4- or 5-oxadiazolyl, 1-, 4- or 5-triazolyl, 2-thiadiazolyl, 3- or 4-pyridazinyl, 2-pyrazinyl, 2-triazinyl, 2-, 3-, 6- or 7-indolizinyl, 2-, 3-, 5- or 6-isoindolyl, 2-, 3-, 5- or 6-benzo [b] furanyl, 2- , 3-, 5- or 6-benzo [b] thiophenyl, 3-, 5- or 6-indazolyl, 2-, 5- or 6-benzthiazolyl, 2-, 5- or 6-benzimida Zolyl, 2-, 3-, 6- or 7-quinolinyl, 3-, 6- or 7-isoquinolinyl, 2- or 8-furinyl, 2-, 3-, 7- or 8-qui Teasing, 3-, 6- or 7-cinnoli , 6- or 7-phthalanyl, 2-, 3-, 6- or 7-quinoxalinyl, 2-, 3-, 6- or 7-naphthyridinyl, 2-, 6- or 7- puteri R ⁶² , which is aryl selected from the group consisting of diyl and 2-, 6- or 7-quinazolinyl;
(B) methyl, which may be mono- or polysubstituted with a fluorine atom and also monosubstituted with R ⁶² ,
(C) branched or straight chain alkyl of 2 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, wherein the alkyl or cycloalkyl group may be mono- or polysubstituted by halogen or oxo,
(D) a group of formula -COOR ⁷³ wherein R ⁷³ is straight or branched chain alkyl of 1 to 5 carbon atoms or cycloalkyl of 3 to 5 carbon atoms,
(E) R ⁷⁴ and R ⁷⁵ are each independently a hydrogen atom, alkyl or fluoroalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or acyl of 1 to 7 carbon atoms, or R ⁷⁴ and R ⁷⁵ between A group of formula -NR ⁷⁴ R ⁷⁵ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms which together with the nitrogen atom of form a heterocyclic ring, one of R ⁷⁴ and R ⁷⁵ may also be a group R ⁶² ,
(F) R ⁷⁶ and R ⁷⁷ are each independently a hydrogen atom, alkyl having 1 to 6 carbon atoms or fluoroalkyl or cycloalkyl having 3 to 6 carbon atoms, or R ⁷⁶ and R ⁷⁷ together with a nitrogen atom therebetween A group of formula -CONR ⁷⁶ R ⁷⁷ which constitutes a saturated hydrocarbon bridge of 3 to 5 carbon atoms forming a click ring, wherein one of R ⁷⁶ and R ⁷⁷ can also be a group R ⁶² ,
(G) a group of formula -COR ⁷⁸ wherein R ⁷⁸ is a hydrogen atom, straight or branched chain alkyl of 1 to 5 carbon atoms, cycloalkyl of 3 to 5 carbon atoms or R ⁶² ,
(H) a group of formula -OR ⁷⁹ wherein R ⁷⁹ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
(I) a group of formula -SR ⁸⁰ wherein R ⁸⁰ is a hydrogen atom, an alkyl, fluoroalkyl or acyl group having 1 to 7 carbon atoms or R ⁶² ,
(J) cyano,
(K) nitro, or
(L) can be replaced with halogen,
R ⁴ is Cl or trifluoromethyl,
R ⁵ and R ⁶ are each independently hydrogen, fluorine, chlorine, bromine or iodine atoms, methyl or trifluoromethyl.
[17" claim-type="Currently amended] A pharmaceutical comprising a pharmaceutically acceptable carrier and a compound according to claim 2, 3, 4, 5, 6, 7, 8, 9 or 10. Composition.

类似技术:

---

公开号 | 公开日 | 专利标题

---

Dubocovich et al.1997|Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor

---

CN105263915B|2019-04-12|Glutamine enzyme inhibitor and application method

---

EP1258252B1|2010-04-21|Integrin expression inhibitors

---

AU736595B2|2001-08-02|Heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists

---

US5866579A|1999-02-02|Imidazole and imidazoline derivatives and uses thereof

---

US6566367B2|2003-05-20|Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines

---

KR101269420B1|2013-05-30|Novel compounds of reverse turn mimetics and the use thereof|

---

ES2258476T3|2006-09-01|Certain heterocicles replaced with rentals.

---

KR100996828B1|2010-11-29|1H-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-CB1 receptor ligands

---

AU776496B2|2004-09-09|Imidazoimidazoles and triazoles as anti-inflammatory agents

---

JP2568315B2|1997-01-08|Fused ring aryl substituted imidazole

---

CN108350062A|2018-07-31|Targeting proteins are degraded to weaken the relevant bad inflammatory reaction of adoptive T cell therapy

---

US6838439B2|2005-01-04|Heterocytes as inhibitors of leucocyte adhesion and as VLA-4 antagonists

---

AU782763B2|2005-08-25|Cyclic amidine compounds

---

Winn et al.1996|2, 4-diarylpyrrolidine-3-carboxylic acids potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722

---

DE69833654T2|2006-12-14|Biaryl alkanic acids in use as cell adhesion inhibitors

---

AU2001285230B2|2007-01-25|Selective androgen receptor modulators and methods of use thereof

---

US5202424A|1993-04-13|Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof

---

TW498076B|2002-08-11|Modified amino acids and pharmaceutical compositions containing these compounds

---

Cirillo et al.1990|Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin.

---

EP0610743B1|1998-09-09|Aminomethylene-peptides as immunosuppressants

---

TW201815766A|2018-05-01|Compounds and methods for IDO and TDO modulation, and indications therefor

---

EP0812331B2|2007-08-08|Mhc-antigen complexes for detecting and purifying antigen-specific t cells

---

Carpéné et al.1995|Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.

---

Ondetti et al.1977|Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents

同族专利:

---

公开号 | 公开日

---

DE69811867T2|2003-11-20|

---

DE69811867D1|2003-04-10|

---

AU6541898A|1998-09-22|

---

DK966447T3|

---

BR9811260A|2000-08-08|

---

WO1998039303A1|1998-09-11|

---

AT233738T|2003-03-15|

---

BG103711A|2001-09-28|

---

PL336580A1|2000-07-03|

---

PT966447E|2003-07-31|

---

TR199902124T2|2000-06-21|

---

EA199900758A1|2000-04-24|

---

EP0966447B1|2003-03-05|

---

HU0002347A2|2000-10-28|

---

CN1249748A|2000-04-05|

---

SK117499A3|2000-05-16|

---

JP2001513821A|2001-09-04|

---

NO994256D0|1999-09-02|

---

EE9900481A|2000-06-15|

---

CA2278547A1|1998-09-11|

---

NO994256L|1999-11-02|

---

DK0966447T3|2003-06-23|

---

IL130931D0|2001-01-28|

---

ES2191286T3|2003-09-01|

---

EP0966447A1|1999-12-29|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1997-03-03|Priority to US4001197P

---

1997-03-03|Priority to US60/040,011

---

1998-03-03|Application filed by 데이비드 이. 프랭크하우저, 베링거 인겔하임 파마슈티칼즈, 인코포레이티드

---

2000-12-26|Publication of KR20000075893A

优先权:

---

申请号 | 申请日 | 专利标题

---

US4001197P| true| 1997-03-03|1997-03-03|

---

US60/040,011|1997-03-03|